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ABSTRACT 
 
 
THE MECHANICAL PROPERTIES OF NON-FAILING 
AND FAILING HUMAN MYOCARDIUM 
 
Heart failure is a clinical syndrome that manifests when there are structural and 
functional impairments to the heart that reduces the ability of the ventricles to fill 
or eject blood. The syndrome affects ~6 million Americans and is responsible for 
nearly 300,000 deaths annually. At the core of the syndrome are dysfunctional 
sarcomeres, the machinery that drives cardiac contraction and relaxation. By 
assessing the mechanical properties of human cardiac tissue, the information 
provided in this dissertation will provide data that demonstrates how sarcomeric 
dysfunction contributes to heart failure in the left and right ventricles. Additionally, 
these data will supply information on how probable therapeutics impact the 
mechanical properties of the heart and the clinical implications. Thus, the overall 
objective of this project is to assess the mechanical properties of failing and non- 
failing human myocardium while concomitantly studying the molecular 
mechanisms contributing to heart failure and work towards therapy. 
 
 
Mechanical experiments were performed with human cardiac samples obtained 
from patients who were receiving heart transplants and from organ donors who 
did not have a history of heart failure. Cardiac samples were homogenized and 
chemically permeabilized (pores in the membrane). Multicellular preparations 
from failing and non-failing hearts were attached between a force transducer and 
a motor to determine the mechanical properties. 
 
 
In the first study, we compared the mechanical properties of cardiac samples 
from the right and left ventricles of non-failing and failing hearts, as well as 
determined the relative phosphorylation levels of specific sarcomeric proteins. 
The results show that in non-failing hearts, calcium sensitivity was higher in the 
left ventricle, and in failing hearts, calcium sensitivity was higher in the right 
ventricle. The shift in the pattern of the calcium sensitivity data from non-failing 
samples to failing samples underpin a statistical interaction between heart failure 
status and the ventricles of the heart for calcium sensitivity. This interaction 
suggests that heart failure is altering the sensitivity of the myofilament to Ca2+ 
differently in the right ventricle. The mechanical data also demonstrated that 
heart failure significantly reduced isometric force and maximum power in both 
ventricles. Biochemical assays suggest that the cause of the interaction observed 
in the calcium sensitivity data is driven by the phosphorylation profile of 
sarcomeric proteins. 
 
 
We then determined the effects of two small molecules (omecamtiv mecarbil and 
para-Nitroblebbistatin) on the mechanical properties of human myocardium. The 
results of those studies demonstrate that omecamtiv mecarbil increases calcium 
sensitivity and slows the rate of force development in a dose-dependent manner 
without altering maximum isometric force. Conversely, para-Nitroblebbistatin 
reduced isometric force, power, and calcium sensitivity without changing 
shortening velocity or the rate of force development. 
 
 
Lastly, we measured the effects of engineered troponins on the mechanical 
function of failing tissue. The results show that troponin C and troponin I 
designed to either increase or decrease calcium sensitivity can significantly 
increase or decrease calcium sensitivity without altering maximum force, 
shortening velocity or the rate of tension development. 
 
 
The findings reported in this dissertation have revealed novel mechanical data 
from non-failing and failing human cardiac tissue. These data present three 
significant results. First, the right vs. left ventricular comparison data shows that 
heart failure in humans reduces maximum force and power in both ventricles 
equally while altering myofilament calcium sensitivity of the left and right 
ventricles in different ways. The change in calcium sensitivity may reflect 
ventricle specific post-translational modifications of sarcomeric proteins. Second, 
the use of myosin modulators revealed that molecules like omecamtiv mecarbil 
and para-Nitroblebbistatin that directly target myosin function can modify calcium 
sensitivity and the rate of force development in human cardiac tissue. Third, the 
engineered troponin study showed that engineered troponins C and I can alter 
myofilament calcium sensitivity without affecting myosin kinetics. Clinically, the 
results of the small molecules and engineered protein studies suggest that small 
molecules and engineered proteins could potentially serve as therapy for patients 
suffering from heart disease. 
 
 
KEYWORDS: Right and left ventricles, human hearts, cardiac specific small 
molecules, calcium sensitivity, sarcomere, engineered proteins 
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CHAPTER 1 
Introduction 
 
 
1.1. The heart as two pumps 
 
The normal mammalian heart is a muscular pump that is divided into four 
chambers, two atria, and two ventricles. The heart can be viewed as two 
separate pumps, the right pump consisting of the right atrium and right ventricle 
(RV) and the left pump composed of the left atrium and left ventricle (LV). The 
atriums sit atop the ventricles where they receive blood from the low-pressure 
venous systems which then makes its way into the ventricles. The RV and LV 
which are separated by the interventricular septum then ejects the blood into the 
low pressure pulmonary and high-pressure systemic systems respectively. As a 
result, the RV is a low-pressure pump, while the LV is a high-pressure pump. 
 
 
The ability of the ventricles to generate adequate pressures to pump blood into 
the pulmonary and systemic vasculature is derived from the capacity of individual 
cardiomyocytes to produce force. There are a series of events that must take 
place for a cardiomyocyte to contract and produce force (electrical stimuli, Ca2+ 
induced Ca2+ release, etc.). However, at the fundamental level, it is the 
shortening of sarcomeres that produces the pressure in the ventricles. Cardiac 
muscle can enhance the amount of force/pressure each ventricle generates by 
increasing sarcomere length. Sarcomere length in the heart increases 
proportionally with preload (stretching of the ventricles because of increased end- 
diastolic volume). Higher preload not only stretch sarcomeres but also increase 
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stroke volume (volume of blood pumped per beat). The mechanism that 
describes the heart’s ability to increase stroke volume and contractility (intrinsic 
ability of the heart to contract independently of preload or afterload) in response 
to an increase in preload is the Frank-Starling mechanism 1 (Fig 1.1). 
 
The right and left pumps must eject similar stroke volumes (volume of blood 
pumped per beat) while working against different afterloads (load/pressure 
imposed on ventricles during ejection. Therefore, each ventricle must generate 
different pressures to eject blood. It is assumed that the thinner RV produces 
lower pressures in comparison to the thicker LV during systole solely because of 
the differences in structure. While it is not debatable that the structure of the 
ventricles contributes to the amount of pressure they can produce, variations in 
the mechanical properties of individual cardiomyocytes could augment the 
geometrical effects. 
 
 
1.2. Right and left ventricular mechanics 
 
Echocardiography and magnetic resonance imaging (MRI) are two techniques 
used to measure the global mechanical function of the RV and LV. The 
mechanical parameters commonly assessed by both methods are strain 
(deformation of an object) and strain rate (strain per unit time) 2. Strain is 
produced when stress (force per unit cross-sectional area) is applied to the walls 
of the ventricles 3. Measuring strain and strain rate can be used to determine the 
velocity of contraction and relaxation, and estimate the filling pressures of the 
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ventricles 4. MRI and echocardiographic measurements are important for 
understanding global pump function. However, neither technique can be used to 
measure mechanical properties at the cellular level. 
 
 
To measure the mechanical properties of the RV and LV at the cellular level, 
researchers have used either intact isolated cells, trabeculae, or papillary muscle 
or permeabilized (single or multicellular preparations with holes in the 
membrane) samples. With intact isolated single cells, an investigator uses a 
high-speed camera to record the mechanical properties when the cell contracts 
and relaxes. Whereas experiments using either intact trabeculae, papillary 
muscle, or permeabilized samples utilize a force transducer and a motor. The 
mechanical parameters that have been reported from isolated intact single cells 
include time to peak contraction and relaxation, the rate of shortening and re- 
lengthening, and time to 50% or 90% relaxation. Studies that have used intact 
trabeculae or papillary muscles have also reported mechanical parameters 
similar to that reported in intact single cells, but have also recorded force/tension. 
 
 
In permeabilized samples, cells are not living, as the membrane has been 
skinned (perforated). However, the contractile structure is still in place, which will 
contract when exposed to Ca2+. Permeabilized samples allow researchers to 
measure contractile properties such as sensitivity of the myofilaments to Ca2+ 
and the rate of force development which cannot be assessed using intact 
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samples. Also, permeabilized samples can also be used to measure maximum 
force, maximum shortening velocity, and power. 
 
 
In animals, both intact and permeabilized tissue from the RV and LV have been 
used to compare the mechanical properties of the ventricles 5-12. In human 13, 
only intact cells have been measured. Data from intact cells have conflicted, 
whereas in permeabilized samples, the results have been more consistent. 
However, the reports from permeabilized samples in animals have raised 
questions as to whether mechanical differences exist in permeabilized samples 
from humans, as the animal data from permeabilized tissue have revealed inter- 
ventricular differences that are not measurable in intact cells. Thus, an 
assessment of the mechanical properties of the RV and LV in intact and 
permeabilized cells is needed to determine if mechanical differences exist 
between the ventricles. 
 
 
1.3. Right and left ventricular differences 
 
The RV and LV of healthy mammalian hearts have different embryologic, 
metabolic, structural, functional, and electrophysiological characteristics. 
However, it is unclear if mechanical differences exist between the cells of the 
ventricles of healthy hearts, and the subsequent effect of heart failure on the 
contractile properties of both ventricles, as previous studies have reported 
inconsistent findings. 
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1.3.1. Embryological origins 
The embryological origins of RV and LV are different (Table 1.1 14). During 
gastrulation, cardiac progenitor cells emerge from the mesodermal layer 15. The 
cardiac progenitors that differentiate into the cardiomyocytes forming the LV 
originate from the primary heart field (first population of cells to migrate to heart- 
forming region), whereas progenitor cells that develop into the RV arise from the 
secondary heart field (second set of cardiac progenitors to migrate into the heart- 
forming region) 14-16. Consequently, there are differences in the genes that 
regulate ventricular formation, such as the basic helix-loop-helix transcription 
factors HAND1 & HAND2, which specifically regulate LV & RV formation 
respectively 14-19. 
 
1.3.2. Functional and structural differences 
 
Under normal physiological conditions, the RV and LV generate different 
pressures to pump the same volume of blood during each cardiac cycle (Table 
1.1 14). The RV creates ~25 mm Hg to pump blood into the low resistance 
pulmonary vasculature, while the LV produces ~120 mm Hg as it ejects blood 
into the high resistance systemic circulation 14. Consequently, by virtue of 
Laplace’s law, the low-pressure RV is thin walled and the high-pressure LV is 
thick walled 20. 
 
The shapes of the ventricles also vary (Table 1.1 14). The LV has a prolate 
ellipsoid shape, a contrast to the elaborate RV that is triangular when viewed 
from the side and crescent shaped when viewed in cross-section 21,22. 
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Additionally, the ventricles show clear anatomical differences in myocardial 
architecture. In the LV, cells in the mid-myocardium (middle layer) are arranged 
circumferentially in the short-axis plane of the equator with fibers angles of 20° to 
-20°, whereas the sub-epicardial (outermost layer) and sub-endocardial 
(innermost layer) cells are layered obliquely and helically with fiber angles 
ranging from 30° to 80° 14,21. As a result, the contraction of the LV is 
circumferential and radial with added rotational and twisting motions 14. 
Conversely, myocytes in the RV are arranged predominantly longitudinal, 
creating the peristaltic contraction seen in the RV 22. 
 
1.3.3. Metabolic and electrophysiological differences 
 
The RV and LV pump the same stroke volume. However, because of the low 
resistance of the pulmonary circulation, the stroke work of the RV is ~75% less 
than that of the LV. As a result, the RV is not as metabolically active 20. 
 
Electrophysiological differences between the RV and LV has been reported in 
healthy mice 5,23, rats 24, dogs 25,26, and guinea pigs 27. In humans, differences 
have been reported between the ventricles of diseased hearts28. However, the 
nature of the electrophysiological difference varies amongst species. In rodents 
(mice and rats), the action potential duration of the RV is shorter than the action 
potential duration in the LV 5,29, while in larger mammals (dogs), the notch during 
phase 1 of the action potential is smaller in LV compared to the RV 26. In small 
and larger animals, functional differences in the electrophysiological properties of 
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the RV and LV have mainly been the result of differential expression and activity 
of K+ channels in the ventricles 30. In rats, Clark et al. 29 demonstrated that the 
heterogeneity seen in the action potential waveforms between the RV and LV is 
the result of the variance in the distribution of transient outward K+ currents. In 
larger dogs, Di Diego and colleagues 26 also showed that the primary reason for 
the differences in the phase 1 notch between the RV and LV is because of higher 
transient outward K+ currents in the RV. Kondo et al. 5 in mice went one step 
further in that they not only showed that interventricular differences in K+ currents 
exist, but they also demonstrated that mechanically cells from the RV and LV 
differ as a result of electrophysiological variances. 
 
 
1.3.4. Mechanical properties in the RV and LV 
 
Studies that have compared the mechanical properties of non-failing RV and LV 
have used intact and permeabilized cells from several different models (Table 
1.2). In intact isolated single cells, the data are inconclusive. Reports from 
healthy cats 12, and human 13 have shown that cells from both chambers behave 
similarly. Conversely, studies using intact single cells from pigs 8 and mice 5 have 
shown differences. In pigs, the RV shortened more than the LV, whereas, in 
mice, cellular shortening was greater in the LV. 
 
 
Mechanical data comparing the RV and LV using intact papillary muscles, 
trabeculae, and permeabilized samples have been more consistent. For 
example, in intact papillary muscles from dogs 9 and rats 11, force was similar in 
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both ventricles. Force was also similar between the RV and LV of intact 
trabeculae 6 and permeabilized 7,10 tissues from rats. In addition to the 
mechanical force data, the two studies that have compared the sensitivity of the 
myofilaments to Ca2+ in rats have also been consistent in that they both showed 
that the LV was more sensitive to Ca2+ in non-failing preparations. Furthermore, 
studies using permeabilized samples demonstrated that heart failure had a 
significant effect on the mechanical properties of the ventricles, which studies in 
intact samples have also shown (Table 1.3). Thus, experiments using 
permeabilized human myocardium from the RV and LV are needed to (1) 
determine if the inter-ventricular differences observed in rats are also present in 
human hearts, and (2) assess the impact of heart failure on the mechanical 
properties of both chambers. 
 
 
1.3.5. Right-sided and left-sided heart failure 
 
Heart failure is a clinical syndrome that manifests when there are structural and 
functional impairments to the heart that reduce the ability of the ventricles to fill or 
eject blood 31. There are more than 23 million people worldwide who are affected 
by the disease, of which, ~6 million are Americans 32,33. The mortality rate for 
heart failure is high, as ~50% of patients die within the first five years of diagnosis 
34-36. 
 
 
Patients who suffer from heart failure can have right-sided dysfunction, left-sided 
dysfunction, or dysfunction in both ventricles. Clinically, RV dysfunction has been 
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under-appreciated, as it was believed that RV failure was primarily a result of 
impaired LV function 37,38. However, several studies have shown that left-sided 
and right-sided heart failure can develop independently of each other 39-43. These 
are important findings because they imply that it might be useful to develop 
chamber-specific therapies to help patients who have predominantly left or 
mostly right-sided dysfunction. Data quantifying the mechanical properties of 
cells from the RV and LV could be used to identify potential therapeutic targets. 
 
 
1.4. Systolic dysfunction 
 
Diastolic and systolic heart failure are the two most common forms of the 
syndrome encountered in clinical practice 44. These forms of heart failure are the 
result of either diastolic (impaired ventricular relaxation, compliance or filling) or 
systolic (impaired contractile or pump function) dysfunction. In comparison to a 
normal heart, patients suffering from diastolic dysfunction had similar stroke 
volume but reduced left ventricular relaxation and increased passive stiffness 45. 
Consequently, these patients have increased pressures during diastole, which 
can be represented by the pressure-volume loop as an upward shift during filling 
(Fig 1.2 46). The hallmark of systolic dysfunction is a reduction in stroke 
volume/ejection fraction (Fig 1.2 46), which leads to the inability of the heart to 
supply enough blood to meet basal metabolic demands 47. 
 
Studies have shown that patients who suffer from diastolic heart failure may not 
experience systolic heart failure. For example, Baicu et al. 48 demonstrated that 
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left ventricular systolic performance, function and contractility, in general, 
remains normal in patients who have diastolic heart failure. However, patients 
who have systolic heart failure almost certainly have diastolic heart failure as well 
49. As a result, patients suffering from systolic heart failure not only display 
reduced stroke volume/ejection fraction, but they also exhibit increased filling 
pressures (Fig.1.2 46). The principal mechanism responsible for systolic heart 
failure is impaired contractile function 45,46. Thus, a lot of attention has been given 
to understanding contractile proteins and ways to improve contractile function. 
 
 
1.5. The sarcomere 
 
The sarcomere is the basic unit of muscle. Each sarcomere is bound by two Z- 
discs which enclose the thin (actin-containing) and thick (myosin-containing) 
filaments (Fig. 1.3A 50). There are hundreds of proteins found in the sarcomere. 
However, it is the proteins comprising the thick and thin filaments that drive 
muscle contraction. The proteins directly involved in carrying out a muscle 
contraction in the thin filament are, actin, the polymerized backbone, 
tropomyosin, a filamentous protein that wraps around action monomers inhibiting 
the interaction between actin and myosin, and the troponin complex (Fig. 1.3B 
50). The trimeric troponin complex consists of troponin C (cTnC), the Ca2+ binding 
subunit, troponin T (cTnT), the subunit that binds the troponin complex to 
tropomyosin, and troponin I (cTnI), the inhibitory subunit 51. 
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The thick filaments consist of the molecular motor myosin II and associated 
proteins, including the cardiac modulatory protein myosin binding protein C 
(cMyBP-C) 52 (Fig. 1.3B 50). Myosin has two heavy chains and four light chains. 
The myosin heavy chains contain three regions, a head (also referred to as either 
the motor domain, cross-bridge or subfragment 1 (S1)), a neck, and a tail 53. The 
motor domain has the ATPase and the actin binding sites which respond to ATP 
binding. Attached to the motor domain are essential (ELC) and regulatory (RLC) 
light chains, which can alter the function of the cross-bridges 54. 
 
1.5.1. Cross-bridge cycle 
 
Muscle contracts when thick and thin filaments slide past each other 55. The 
process is initiated by an action potential which causes an increase in 
intracellular Ca2+ through a process termed Ca2+-induced Ca2+-release 56. High 
amounts of Ca2+ then binds to cTnC resulting in the conformational change of the 
troponin complex. The structural alteration in the troponin complex then leads to 
a shift in tropomyosin exposing binding sites on actin for myosin cross-bridges to 
bind 57. The attachment of actin and myosin because of increased Ca2+ sets the 
stage for the thick and thin filaments to slide past each other and generate force 
through the actions of the cross-bridges. 
 
 
Lymn and Taylor first proposed the cross-bridge cycle in 1971 58. It explains the 
kinetic properties of the actin-myosin complex during a contraction 59-61 (Fig. 1.4 
62). The binding of myosin to actin in the presence of ATP initiates the cross- 
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bridge cycle, which stimulates the ATPase in the cross-bridges 53. In the absence 
of ATP, the actin-myosin interaction forms a strong (rigor) complex. Upon the 
binding of ATP to the ATPase, cross-bridges briefly dissociate from actin and 
then re-attaches through weak hydrostatic bonds (step 1). The hydrolysis of ATP 
to ADP + Pi then causes a conformational shift in the heads of the cross-bridges 
leaving the myosin heads in a pre-stroke position (step 2). This reaction (ATP to 
ADP + Pi) primes the cross-bridges for re-attachment to actin in a more strongly 
bound force-producing state (step 3). During the transition period where the 
myosin-actin interaction goes from a weakly to a strongly bound state, inorganic 
phosphate is released leaving ADP (weakly bound to strongly bound are 
represented in figure 1. 4 62 as 3a for weakly bound and 3b for strongly bound). 
The next step in the cycle is the force producing state, as the release of inorganic 
phosphate causes a conformational shift of the heads of cross-bridges (~10 nm), 
pulling actin filaments towards the center of the sarcomere, this is referred to as 
the “power stroke” (step 4). The final step in the cycle (step 5 Fig. 1.4 62) is the 
release of ADP which leaves cross-bridges and actin in a rigor state until the next 
ATP molecule binds starting the cycle again. 
 
 
The weakly to the strongly bound transition period of the cross-bridge cycle 
(steps 3a and 3b in Fig. 1.4 62) is of great importance, as it serves as a molecular 
target for therapy for patients suffering from heart conditions. Studies have 
shown that this transition period can be altered with drugs. For examples, reports 
in dogs 63 and rats 64 show that the cardiac myosin activator omecamtiv mecarbil 
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increased the rate of inorganic phosphate release which forces cross-bridges into 
the strongly bound force-producing state faster. Conversely, Blebbistatin a small 
molecule that inhibits myosin II function has been shown to slow down the 
release of inorganic phosphate during the weakly to strongly bound transition 
state, trapping cross-bridges in weakly bound state longer 65-68. The use of these 
compounds or similar molecules may serve as therapy for patients suffering from 
systolic heart failure, or hypertrophic (hypercontractility) cardiomyopathy 
respectively. 
 
 
The use of small molecules to modulate the cross-bridge cycle to improve 
cardiac function may serve as a plausible option for patients suffering from 
cardiac diseases. However, some cardiomyopathies are the result of mutations in 
contractile proteins. Therefore, small molecules may not be beneficial to these 
patients. Another area of research that has proved a therapeutic option for 
patients suffering from cardiac disease is gene therapy. Thus, there is ongoing 
research trying to devise ways to alter the contractile function of the heart by 
modifying sarcomeric proteins. The modifications that are made to these proteins 
are then used to replace dysfunctional proteins or change the phosphorylation 
status of a particular sarcomeric protein to improve cardiac function. 
 
 
1.5.2. Phosphorylation of myofilament proteins 
 
The heart must continually adapt to changes in hemodynamic load as well as 
respond to neurohumoral stresses on a beat-to-beat basis. To handle the 
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constant changes, dynamic regulation of contractile apparatus is needed. Post- 
translational modification of sarcomeric proteins is a primary mechanism for 
altering cardiac function on a beat-to-beat basis 69,70. One of the most studied 
post-translational modifications is phosphorylation 71. In the sarcomere, studies 
have shown that phosphorylation of thin and thick filament proteins can promote 
or depress cross-bridge kinetics 72,73. Additionally, alteration in contractile protein 
structure and function by post-translational modifications have been implicated in 
heart failure 74,75. 
 
There are several known kinases (ex. Serine/Threonine kinases such as protein 
kinases A, C, D, G, & Ca2+/calmodulin protein kinase II) and phosphatases (ex. 
protein phosphatase I) that modulate contractile protein function 76. The known 
targets of these kinases and phosphatases are cTnI, cTnT, and tropomyosin in 
the thin filament, 77-79 and MyBP-C and RLC in the thick filament 80-83. Stimulation 
of the α and β adrenergic receptors on cardiomyocytes can enhance or reduce 
contractile protein phosphorylation by augmenting or decreasing kinase or 
phosphatase activity 84. One of the most studied pathways that are used to alter 
kinase activity in the heart is the β-adrenergic pathway. At the contractile protein 
level, β-adrenergic stimulation has been shown to enhance PKA levels which 
phosphorylate several contractile proteins including cTnI. 
 
 
The phosphorylation of cTnI is of importance in the forthcoming chapters, as 
phosphorylation of this protein is known to alter myofilament Ca2+ sensitivity 85, a 
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mechanical parameter measured in these studies. In chapter 5, the effects of 
engineered cTnI and cTnC on Ca2+ sensitivity are discussed. 
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1.6. Overall objective 
 
The overall aim of this project is to assess the mechanical properties of failing 
and non-failing human myocardium while concomitantly studying the molecular 
mechanisms contributing to heart failure and work towards therapy. 
 
 
1.6.1. Compare the mechanical properties of the RV and LV of non-failing 
and failing human hearts. (Chapter 2) 
Hypothesis: Myocardium from the RV and LV of human hearts has different 
mechanical properties. 
Rationale: The RV and LV of human hearts have different embryologic, 
metabolic, structural, functional, and electrophysiological characteristics. 
However, it is unclear if mechanical differences exist between the chambers in 
non-failing and failing hearts. 
 
 
1.6.2. Determine the effects of omecamtiv mecarbil on the mechanical 
properties of failing human hearts. (Chapter 3) 
Hypothesis: The cardiac myosin activator omecamtiv mecarbil will augment 
mechanical force. 
Rationale: Omecamtiv mecarbil is a drug design to enhance the rate of inorganic 
phosphate release in the actin-myosin cycle. By increasing the rate of phosphate 
release, the molecule increases the number of myosin heads strongly bound to 
actin at any given time during the cross-bridge cycle. Thus, cardiac tissue 
incubated with the drug should produce higher mechanical forces. 
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1.6.3. Assess the effects of para-Nitroblebbistatin on the mechanical 
properties of failing human hearts. (Chapter 4) 
Hypothesis: Para-Nitroblebbistatin will decrease the maximum force and calcium 
sensitivity in human cardiac samples incubated with the molecule. 
Rationale: para-Nitroblebbistatin is a molecule designed to keep cross-bridges in 
the weakly bound state with actin. Therefore, failing tissue incubated with the 
molecule should produce less force and have lower calcium sensitivity as a result 
of the molecule reducing the duty ratio (number of myosin heads in strong force 
generating state). 
 
 
1.6.4. Examine the effects of engineered proteins on the mechanical 
properties of failing human myocardium. (Chapter 5) 
Hypothesis: Cardiac troponins C and I engineered to increase or decrease Ca2+ 
sensitivity will alter pCa50. 
Rationale: The effects of engineered troponins C and I have been demonstrated 
in vivo in rodent myocardium. However, how these proteins change the 
mechanical properties of human samples is not known. By showing similar 
effects in human hearts, engineered troponins C & I may serve as therapy for 
patients suffering heart failure. 
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Figure 1.1. The Frank-Starling mechanism 
Curves represent a change in stroke volume in response to increasing preload. 
Red line (heart failure), blue (normal healthy hearts), green (when contractility is 
increased in the heart). 
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  Table 1.1. Differences between the left and right ventricles under normal conditions  
 Left ventricle Right ventricle 
Embryological origin Primary heart field Secondary heart field 
Morphological 
characteristics 
Bullet shape; prolate ellipsoid Complex, crescentic 
Myocardial characteristics Thick smooth walls; fine 
trabeculations 
Thin, heavily trabeculated 
walls 
Myocardial architecture Predominant radial myocyte 
orientation in the mid layers; 
subendocardial myocytes follow 
right-hand helix configuration; 
subepicardial myocytes form left- 
hand helix 
Predominant longitudinal 
myocyte orientation; 
angulated intrusion of 
superficial myocytes toward 
the endocardium 
Physiological pump 
conditions 
High-resistance, high-pressure 
pump; dominant radial thickening 
and contraction during ejection 
Low-resistance, low- 
capacitance pump; 
peristaltic-like motion from 
inflow to outflow during 
ejection 
Flow characteristics Well-defined isovolumic 
contraction and relaxation; no 
hangout period 
No or minimal isovolumic 
periods; hangout period 
Table modified from Friedberg & Redington, 201414 
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Table 1.2. Non-failing mechanical properties in the RV and LV reported in the literature 
Model (Intact 
cells/trabeculae/papillary 
muscle/permeabilized) 
Mechanical 
property 
Non-failing 
RV 
Non- 
failing 
LV 
RV vs. LV 
comparison 
Cats (intact cells)12 Rate of shortening 
(resting lengths/s) 
0.67 ± 0.19 0.67 ± 
0.12 
Not significant 
 
Rate of relaxation 
(resting lengths/s) 
0.69 ± 0.22 0.69 ± 
0.18 
Not significant 
 
Extent of 
contraction (% of 
resting length) 
10.6 ± 2.6 10.6 ± 1.5 Not significant 
Dogs (papillary muscle)9 Total tension 
(g/mm2) 
7.2 ± 1.6 7.9 ± 1.7 Not significant 
 
Maximum rate of 
tension 
development 
(mm2/g/s) 
31.8 ± 8 28 ± 4 Not significant 
 Time to peak 
tension (ms) 
336 ± 26 401 ± 42 Significant 
difference 
(p<0.005) RV 
reached peak 
tension faster 
Pigs (intact cells)8 Percent shortening 
(%) 
5.7 ± 0.2 4.6 ± 0.1 Significant 
difference 
(p<0.05) RV 
shortened 
more 
 
Velocity of 
shortening (µm/s) 
87 ± 4 50 ± 1 Significant 
difference 
(p<0.05) RV 
shortened 
faster 
 
Velocity of re- 
lengthening (µm/s) 
80 ± 4 50 ± 1 Significant 
difference 
(p<0.05) RV 
re-lengthened 
faster 
 
Time to peak 
contraction (ms) 
200 ± 4 247 ± 4 Significant 
difference 
(p<0.05) RV 
contracted 
faster 
 
Time to 50% 
relaxation (ms) 
98 ± 3 101 ± 2 Not significant 
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Rats (papillary muscle)11 Time to peak force 
(ms) 
130 ± 3 151 ± 4 Significant 
difference 
(p<0.01) RV 
reached peak 
force faster 
 Active force 
(g/mm2) 
6.0 ± 0.4 6.2 ± 04 Not significant 
 Maximum rate of 
force development 
(g/mm2/s) 
74 ± 6 70 ± 4 Not significant 
 Maximum 
shortening (%) 
18 ± 1 13 ± 0.5 Significant 
difference 
(p<0.05) RV 
shortened 
more 
 
Maximum 
shortening velocity 
(muscle lengths/s) 
1.98 ± 0.14 1.13 ± 
0.07 
Significant 
difference 
(p<0.05) RV 
shortened 
faster 
Rats (trabeculae)6 Force (mN/mm2) Values not 
presented 
(figure) 
Values not 
presented 
(figure) 
Not significant 
Mice (intact cells)5 Sarcomere length 
shortening (µm) 
0.033 ± 
0.003 
0.041 ± 
0.003 
Significant 
difference 
(p<0.01) LV 
shortened 
more 
 
Rise time (50% to 
peak, ms) 
54.7 ± 1 51 ± 1 Not significant 
 
Decay time (50% to 
baseline, ms) 
117 ± 5 98 ± 3 Significant 
difference 
(p<0.01) LV 
decay faster 
Human (intact cells)13 Time to peak 
shortening (s) 
Values not 
presented 
(figure) 
Values not 
presented 
(figure) 
Not significant 
 
Time to relaxation 
(s) 
Values not 
presented 
(figure) 
Values not 
Presented 
(figure) 
Not significant 
 
Rats (Permeabilized 
cells)7 
Maximum force 
(mN/mm2) 
28.1 ± 1.7 26.7 ± 1.3 Not significant 
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 EC50 (µmol/L) ( 1.77 ± 0.01 1.36 ± 
0.06 
Significant 
difference 
(p<0.05) LV 
more sensitive 
to Ca2+ 
Rats (Permeabilized 
strips)10 
Maximum force 
(mN/mm2) 
0.85 ± 0.15 1.5 ± 0.25 Not significant 
 pCa50 5.7 ± 0.09 6.0 ± 0.05 Significant 
difference 
(p<0.05) LV 
more sensitive 
to Ca2+ 
*EC50 & pCa50 indicates the Ca2+ concentration at 50% of maximum force, and is the index for 
myofilament Ca2+ sensitivity. 
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Table 1.3. Comparison of non-failing and failing RV and LV mechanical properties 
reported in the literature 
Model (Intact 
cells/trabeculae 
/permeabilized) 
Mechanic 
al 
property 
Non- 
failing 
RV 
Non- 
failing 
LV 
Failing 
RV 
Failing 
LV 
Non-failing RV & 
LV vs. Failing RV 
& LV 
Pigs (intact 
cells)8 
Percent 
shortening 
(%) 
5.7 ± 
0.2 
4.6 ± 
0.1 
3.1 ± 
0.1 
2.3 ± 
0.1 
Significant 
difference 
(p<0.05) Failing 
RV & LV 
shortened less 
than non-failing 
RV & LV. Failing 
LV shortened less 
than failing RV 
 
Velocity of 
shortening 
(µm/s) 
87 ± 4 50 ± 1 48 ± 2 33 ± 1 Significant 
difference 
(p<0.05) Failing 
RV & LV velocity 
of shortening was 
slower than Non- 
failing RV & LV. 
Failing LV velocity 
of shortening was 
slower than failing 
RV 
 
Velocity of 
re- 
lengthenin 
g (µm/s) 
80 ± 4 50 ± 1 50 ± 3 32 ± 1 Significant 
difference 
(p<0.05) Failing 
RV & LV re- 
lengthened 
slower. Failing LV 
re-lengthened 
slower than failing 
RV 
 
Time to 
peak 
contractio 
n (ms) 
200 ± 4 247 ± 4 242 ± 4 234 ± 4 Significant 
difference 
(p<0.05) Failing 
RV took longer to 
get to peak 
contraction, and 
failing LV got to 
peak contraction 
faster than non- 
failing LV 
 Time to 
50% 
relaxation 
(ms) 
98 ± 3 101 ± 2 102 ± 3 105 ± 3 Not significant 
Rats 
(trabeculae)6 
Force 
(mN/mm2) 
Values 
not 
present 
Values 
not 
present 
Values 
not 
present 
Values 
not 
present 
Not significant 
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  ed 
(figure) 
ed 
(figure) 
ed 
(figure) 
ed 
(figure) 
 
Human (intact 
cells)13 
Time to 
peak 
shortening 
(s) 
Values 
not 
present 
ed 
(figure) 
Values 
not 
present 
ed 
(figure) 
Values 
not 
present 
ed 
(figure) 
Values 
not 
present 
ed 
(figure) 
Not significant 
 
Time to 
relaxation 
(s) 
Values 
not 
present 
ed 
(figure) 
Values 
not 
Present 
ed 
(figure) 
Values 
not 
present 
ed 
(figure) 
Values 
not 
Present 
ed 
(figure) 
Not significant 
Rats 
(Permeabilized 
cells)7 
Maximum 
force 
(mN/mm2) 
28.1 ± 
1.7 
26.7 ± 
1.3 
14.9 ± 
1.0 
13.3 ± 
0.8 
Significant 
difference 
(p<0.05) Failing 
RV & LV produced 
less force 
 
EC50 
(µmol/L) 
1.77 ± 
0.01 
1.36 ± 
0.06 
1.59 ± 
0.08 
2.42 ± 
0.18 
Significant 
difference 
(p<0.05) Non- 
failing LV is more 
sensitive to Ca2+ 
than failing LV 
Rats 
(Permeabilized 
strips)10 
Maximum 
force 
(mN/mm2) 
0.85 ± 
0.15 
1.5 ± 
0.25 
1.7 ± 
0.35 
1.7 ± 
0.27 
Significant 
difference 
(p<0.05) Failing 
RV produce more 
force than non- 
failing RV 
 
pCa50 5.7 ± 
0.09 
6.0 ± 
0.05 
6.0 ± 
0.09 
6.0 ± 
0.09 
Significant 
difference 
(p<0.05) Failing 
RV is more 
sensitive to Ca2+ 
than non-failing 
RV. 
*EC50 & pCa50 indicates the Ca2+ concentration at 50% of the maximum force and is the index for 
myofilament Ca2+ sensitivity. 
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Figure 1.2. Left Ventricular Pressure-Volume Loops in Systolic and 
Diastolic Dysfunction 
A) Systolic dysfunction with decreased stroke volume, black line displaced 
downward. B) Normal pressure-volume loop. C) Diastolic dysfunction, the 
diastolic pressure has shifted up (solid curved black line). (Modified from 
Aurigemma and Gaasch, 2004 46) 
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Figure 1.3. Sarcomere 
 
A) Schematic of sarcomere bounded by two Z-disc with thick and thin filaments. 
 
B) Close up of selected thin and thick filament proteins. Thin filament proteins: 
actin, tropomyosin (TM), troponin C (TnC), troponin T (TnT), troponin I (TnI); 
thick filament proteins: SI subfragment/cross-bridges (S1), myosin binding 
protein C (MyBP-C), regulatory light chain (RLC), essential light chain (ELC), 
lever arm (S2), light meromyosin (LMM). (Modified from Hwang and Sykes, 2015 
50) 
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Figure 1.4. Actin-myosin cross-bridge cycle 
 
Yellow cross-bridges represent actin and myosin in the weakly bound state; red 
cross-bridges represent actin and myosin in the strongly bound state. Step 1: 
Binding of ATP to cross-bridge dissociates myosin heads from actin. Step 2: 
Hydrolysis of ATP to ADP + Pi locking myosin heads in pre-stroke configuration. 
Step 3 (a and b): Transition of actin-myosin interaction from weakly bounded to 
strong binding, which results from the release of inorganic phosphate. Step 4: 
Powerstroke, cross-bridges shift ~10-nm pulling actin to the center of the 
sarcomere. Step 5: ADP released, actin and myosin remain in rigor until new 
ATP binds. (Adapted from James Spudich, 2014 62) 
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Chapter 2 
 
The Ca2+ sensitivity of right ventricular myocardium increases more than 
the Ca2+ sensitivity of left ventricular myocardium in human heart failure 
 
2.1. Introduction 
In healthy human hearts, the left ventricle (LV) is a thick-walled bullet shaped 
chamber that generates high pressure (~120 mm Hg during systole) to pump 
blood around the systemic circulation. Conversely, the right ventricle (RV) is a 
thinner crescent shaped low-pressure pump that produces ~25 mm Hg as it 
ejects blood into the pulmonary vasculature 5,14. While it is clear that the distinct 
chamber structures contribute to the inter-ventricular difference in systolic 
pressure, it is not known if variation in myocardial contractile properties 
augments the geometrical effects. Neither is it known whether heart failure 
affects cells from the LV and the RV in the same way. 
 
 
The impact of heart failure on LV myocardial function has been reported 
extensively. Studies using skinned cardiac samples from patients with end-stage 
heart failure have shown that the failing heart is more sensitive to Ca2+ and 
develops less contractile force than samples obtained from organ donors who did 
not have heart failure 86-93. However, it is less clear how heart failure alters the 
contractile properties of tissue from the RV. 
 
 
Previous reports that have looked at the effects of heart failure on maximal force 
(Fmax) and Ca2+ sensitivity (pCa50) in the RV and LV have used animal models. 
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Belin et al. 7 demonstrated that heart failure in rats reduced Fmax in permeabilized 
myocytes from both ventricles. Conversely, Perreault and colleagues 10 showed 
that heart failure increased Fmax in the RV and had no effect on the LV. Both 
studies revealed that non-failing cells from the LV are more sensitive to Ca2+ than 
non-failing cells from the RV. In failing tissue, Perreault et al. 10 found that heart 
failure increased pCa50 in the RV but not in the LV, while Belin et al. 7 reported 
that heart failure reduced pCa50 in the LV without altering pCa50 in the RV. 
 
 
The data reported in this manuscript extend these studies to human myocardium. 
Our results show that pCa50 values measured for multicellular preparations from 
non-failing LV were greater than pCa50 values measured for non-failing RV 
specimens. In failing hearts, the opposite was true. Failing RV samples had 
higher pCa50 values than failing LV samples. Data quantifying the relative 
phosphorylation levels of myofilament proteins suggested that the shifts in Ca2+ 
sensitivity reflected changes in the relative phosphorylation of cardiac troponin I 
(cTnI). There were no inter-ventricular differences in maximum force, maximum 
power output or maximum shortening velocity. 
 
 
2.2. Materials and Methods 
 
2.2.1. Procurement of human samples 
 
The human cardiac samples used in this study were acquired using the collection 
protocol described by Blair et al. 94. Briefly, hearts procured from patients 
undergoing cardiac transplants at the University of Kentucky and from organ 
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donors who did not have heart failure were given to a researcher immediately 
after being removed from the patient. The samples were obtained from through- 
wall sections cut from the distal region of the LV and RV. The LV samples were 
then further dissected transmurally, forming sub-epicardial, mid-myocardial, and 
sub-endocardial specimens. RV samples were not separated transmurally, as the 
RV wall is typically thinner and the dissection is harder to perform consistently. 
The specimens were snap-frozen in liquid nitrogen within 30 minutes of being 
removed from the patient and stored in the vapor phase of liquid nitrogen 
at -150°C until use. The University of Kentucky Institutional Review Board 
approved all procedures, and subjects gave informed consent. 
Previous data from our laboratory 95 showed that heart failure has a greater 
impact on the contractile properties of samples from the middle transmural region 
of the LV than on samples from the LV sub-epicardium or LV sub-endocardium. 
This study compared samples from the RV and the mid-myocardium of the LV to 
optimize the probability of detecting statistically significant effects. 
 
 
2.2.2. Clinical characteristics from patients with heart failure and donors 
The samples from patients undergoing heart transplants came from 7 males 
(classification of heart failure: 5 ischemic and 2 non-ischemic) and 5 females 
(classification of heart failure: all non-ischemic). The donor samples came from 3 
males (cause of death: 2 head trauma and 1 unknown) and 2 females (cause of 
death: stroke). The mean age of the patients with heart failure was 48 (range 19 
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to 68), while that of donors was 41 (range 22 to 48). Patients’ characteristics are 
summarized in table 2.1. 
 
 
2.2.3. Multicellular preparations 
 
Multicellular preparations (Fig. 2.1) were obtained by mechanically disrupting 
 
~100 mg of tissue from the LV mid-myocardium or the RV. The preparations 
were then permeabilized using 1% v/v Triton detergent (Fig. 2.1.1). A total of 79 
multicellular preparations from 17 patients (5 non-failing and 12 failing hearts) 
were analyzed. The average length of the preparations used in this study was 
860 ± 248 µm, and the average cross-sectional area was 4.05 ± 2.08 x 10-8 m2. 
Cross-sectional area was estimated assuming a circular profile. 
 
 
2.2.4. Experimental set-up 
 
Preparations were attached to a force transducer (resonant frequency, 600 Hz; 
Model 403, Aurora Scientific, Aurora, Ontario, Canada) and a motor (step time 
0.6 ms; model 312B, Aurora Scientific) (Fig. 2.1.2) and stretched to a sarcomere 
length of 2.24 µm in a solution with a pCa (= -log10[Ca2+] of 9.0. All experimental 
measurements were conducted at 15°C using SLControl software 96. 
 
2.2.5. Solutions 
 
Two set of solutions were used in this study. A relaxing solution to isolate and 
permeabilize preparations, and experimental pCa (= -log10 [Ca2+]) solutions with 
varying concentrations of Ca2+. The relaxing solution contained (in mmol L-1): 4 
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ATP, 2 EGTA, 20 imidazole, 100 KCl and 7 MgCl2. The final pH of the relaxing 
solution was adjusted to 7.0 with 4M KOH. To permeabilize the multicellular 
preparations, double strength relax, water and two protease inhibitors 
(phenylmethlsulfonide 500 µmol L-1 and leupeptin 40 µmol L-1) were added to 
three beakers, the fourth beaker contained the aforementioned and triton. To 
make a range of activating solutions (pCa solutions), two pCa (4.5 & 9.0) 
solutions were initially made. Intermediate pCa solutions ranging from pCa 5.0 to 
6.4 were made by combining different volumes of pCa 4.5 and 9.0. pCa 4.5 
contained (in mmol L-1): 7 EGTA, 20 Imidazole, 52 KCL, 14.5 Creatine 
phosphate, 4.9 ATP, 7 CaCl2, 5.23 mgCl2, sufficient amounts of KOH to get pH to 
7.0. The composition of pCa 9.0 (in mmol L-1) was: 7 EGTA, 20 Imidazole, 68 
KCL, 14.5 Creatine phosphate, 4.83 ATP, 5.41 MgCl2, and 13.7 µM CaCl2 plus 
ample amount of KOH to reach pH 7.0. The ionic strength was held constant at a 
180 mM in all solutions. 
 
 
2.2.6. Force, rate of tension development, Ca2+ sensitivity measurements 
Preparations were initially immersed in pCa 4.5 (saturating Ca2+ concentration). 
Maximum isometric force (Fmax) was calculated as the force developed in this 
solution at steady-state (Fig. 2.1.3). Once force reached steady state, the rate of 
tension development, ktr, was measured by rapidly shortening the preparation by 
20%, holding it at the short length for 20 ms, and then re-stretching the 
preparation to its original length. The ktr was subsequently calculated by fitting 
the portion of the force record immediately after the re-stretch with a single 
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exponential function of the form F(t) = A + B(1-exp(-ktrt)). In this equation, F(t) is 
the force at time t, and A and B are constants (Fig. 2.1.3). Calcium sensitivity 
(pCa50) was determined by repeating the force measurements with different 
solutions that had pCa values in the range 9.0 to 5.0. pCa50 values were 
calculated by fitting the resulting data to a modified Hill equation of the form F = 
Fpas + FCa ([Ca2+]n / ([Ca2+]n + [Ca2+ 50]n)), where Fpas is the force measured in  pCa 
9.0 solution; FCa is Ca2+ activated force; n is the Hill coefficient, and [Ca2+ 50]n is 
the free Ca2+ concentration required to develop half the maximum Ca2+ 
dependent force. 
 
 
2.2.7. Shortening velocity and power measurements 
 
To measure the shortening velocity and power, the multicellular preparations 
were allowed to shorten for 80 ms against pre-set loads that ranged from 0 to 
100% of the maximum tension measured in pCa 4.5 solution. The shortening 
velocity in each trial was determined by fitting a regression line to a plot of fiber 
length against time during the final 50 ms of the force clamp. The mean force 
was also determined during this time. The resulting data were then fitted using a 
hyperbolic equation of the form (F+a) (V+b) = (F0 +a) b, where F is the force 
developed at a shortening velocity of V, F0 is the isometric force, and a and b are 
constants with dimensions of force and velocity respectively. Power values were 
calculated as the product of force and velocity. Fig. 2.1.4 illustrates a 
representative force-velocity and power curves. 
34  
2.2.8. Phosphorylation of myofilament proteins 
 
The phosphorylation status of selected sarcomeric proteins was determined 
using the protocol described in the supplemental materials of Haynes et al. 95. 
Chemically permeabilized multicellular preparations utilized in the mechanical 
measurements were initially homogenized in urea-thiourea sample buffer (in mol 
L−1, 8 Urea, 2 Thiourea, 0.075 M DTT, and 0.05 Tris-HCl, with 3% SDS w/v, pH 
6.8). 1 µg of protein was then loaded onto each lane of precast polyacrylamide 
gels (12% 26 well Tris-HCl, Bio-Rad, Hercules, CA). Gels were first stained with 
Pro-Q Diamond phosphoprotein stain (Invitrogen, Carlsbad, CA) and scanned 
with a Typhoon 9410 scanner (GE Healthcare, Piscataway, NJ) to detect 
phosphorylated proteins. The gels were then de-stained and subsequently 
stained again with Sypro Ruby (Invitrogen, Carlsbad, CA) to assess total protein 
content. The amounts of phosphorylated or total protein represented by each 
band were determined by integrating the densitometry profile followed by 
appropriate background correction. These calculations were performed using 
GelBox software developed by our laboratory. Values from multiple gels were 
normalized using data from a single homogenate that was run on each gel. 
Relative phosphorylation was calculated as the ratio of the integrated densities 
calculated for the Pro-Q Diamond and Sypro Ruby stains. 
 
 
2.2.8.1. Western blot analysis of cTnI Ser-23/24 phosphorylation 
 
TnI Ser23/24 specific phosphorylation was determined by Western blot similar to 
that previously described Nixon et al. 97 and Salhi et al. 98. Briefly, whole cell 
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homogenates from above were separated on a 12% (29:1) Laemmli gel and 
transferred to Immobilon FL PVDF membrane (Millipore Sigma, Billerica, MA). 
Following blocking with 1% BSA in TBS, TnI Ser-23 and Ser-24 phosphorylation 
(pTnI S23/24) was detected by incubation with the rabbit anti-phosphorylated TnI 
Ser-23/24 antibody (Cell Signaling Technology, Inc.). Following washes, 
membranes were incubated with an anti-rabbit Cy5 labeled fluorescent 
secondary antibody (Jackson ImmunoResearch Laboratories, Inc, West Grove, 
PA), washed and visualized on a Typhoon 9410 imager (GE Healthcare, 
Piscataway, NJ). Following TnI Ser-23/24 phosphorylation imaging, total TnI was 
determined in the same membrane by re-incubation with the mouse anti-cardiac 
TnI antibody (Fitzgerald; clone C5). Following washes, the membrane was 
incubated with an anti-mouse Cy2 labeled fluorescent secondary antibody 
(Jackson ImmunoResearch Laboratories, Inc, West Grove, PA), washed again 
and visualized as above. Sequential development using different 
primary/secondary combinations allows for quantification of phosphorylated and 
total TnI species in the same membrane. Phosphorylation at Ser-23/24 and 
expression of TnI was then quantified from the individual images with 
ImageQuant TL v8.0 (GE Healthcare, Piscataway, NJ) and Ser-23/24 
phosphorylation defined in arbitrary units as the TnI Ser-23/24 phosphorylation 
signal divided by the total TnI signal. 
 
 
2.2.9. Statistical analysis 
 
The experimental data were analyzed in SAS 9.4 (SAS Institute, Cary, NC) using 
linear mixed effects models incorporating two main effects (heart failure status 
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and ventricular region) and their interaction. The linear mixed models were 
chosen for the analysis for a few reasons. First, they accounted for the 
unbalanced design (5 non-failing and 12 failing hearts). Second, the linear mixed 
models took into consideration that certain regions (LV and RV) came from the 
same person (repeated measures) and that from that LV or RV sample, there 
were 2 to 3 preparations (hierarchical nesting). Thus, the linear mixed models 
provided more statistical power than a standard two-way ANOVA tests when 
multiple samples from each heart are analyzed. Post-hoc analysis was 
performed using Tukey-Kramer corrections. P values less than 0.05 were 
considered significant. Data are reported as mean ± SEM.
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Table 2.1. Patients’ characteristics  
Age Gender Diagnosis Cardiomyopathy/cause of death 
22 Male Non-failing Head trauma 
60 Female Non-failing Stroke 
28 Male Non-failing Head trauma 
47 Female Non-failing Stroke 
48 Male Non-failing Unknown 
68 Male Failing Ischemic 
42 Male Failing Ischemic 
53 Male Failing Ischemic 
54 Male Failing Ischemic 
64 Male Failing Ischemic 
20 Male Failing Non-ischemic 
35 Male Failing Non-ischemic 
56 Female Failing Non-ischemic 
66 Female Failing Non-ischemic 
19 Female Failing Non-ischemic 
60 Female Failing Non-ischemic 
36 Female Failing Non-ischemic 
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Figure 2.1. Multicellular preparation 
4X magnification of permeabilized multicellular preparation. Each preparation 
used in this and forthcoming studies contained between 10-20 single 
cardiomyocytes. 
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Figure 2.1.1. Permeabilization of preparations 
Top left, human heart displaying right and left ventricles. Top excluding human 
heart, homogenization, and permeabilization (skinning) process. Bottom left, 
intact membrane. Bottom right, permeabilized membrane. 
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Figure 2.1.2. Experimental setup 
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Figure 2.1.3. Experimental record 
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Figure 2.1.4. Representative force-velocity and force-power curves 
A) Top panel, experimental records from one preparation demonstrating different 
forces as a result of being held at different loads. Bottom panel, fiber length 
records from each individual load the preparation was held at. B) Top panel, 
shortening velocity curve. Bottom panel, power curve. 
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2.3. Results 
 
2.3.1. Heart failure has a greater effect on the Ca2 sensitivity of right 
ventricular myocardium 
Fig 2.2A shows that heart failure increased the sensitivity of the myofilaments to 
Ca2+ (main effect for disease status, p=0.006). pCa50 increased from 5.60 ± 0.03 
in the non-failing samples (mean ± sem of all non-failing samples from the LV 
and RV) to 5.71 ± 0.02 in the samples isolated from patients who had heart 
failure. The increase was greater for samples from the right ventricle (ΔpCa50 
~0.18, p<0.001) than for samples from the left ventricle (ΔpCa50 ~0.05, not 
significant). These effects meant that there was a significant interaction (p<0.002) 
between heart failure status and cardiac region for pCa50. A similar statistical 
interaction (p=0.040) was measured for the Hill coefficient n (Fig 2.2B). The 
effects of heart failure on the calcium sensitivity and cooperativity of the 
myofilament thus depend on the ventricle that is being studied. 
 
 
2.3.2. Heart failure reduces maximum force and maximum power output in 
both ventricles 
Fig 2.3 shows that preparations from the right and left ventricles generated 
similar contractile force in maximally activating Ca2+ solution. On average, the 
non-failing samples produced 25.3 ± 7.9 kN m-2, whereas samples from the LV 
and RV of failing hearts produced 14.8 ± 5.2 kN m-2. Heart failure, therefore, 
suppressed force by ~40% in both ventricles. Maximum power (where power was 
measured as the product of force and velocity during loaded shortening) was 
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also significantly reduced by heart failure (p<0.001 for both ventricles) (Fig 2.3B). 
Vmax was not affected by ventricular region or heart failure status. On average, 
Vmax was 1.09 ± 0.36 muscle lengths per second (l0 s-1) (Fig 2.4A). The rate of 
tension development is also similar between the ventricles in non-failing and 
failing preparations, as the average ktr was 0.88 ± 0.15 s-1 (Fig 2.4B). 
 
2.3.3 Heart failure alters phosphorylation of myofilament proteins 
 
The phosphorylation status of cTnI, cardiac myosin binding protein-C (cMyBP-C), 
and myosin regulatory light chain (RLC) were assessed using Pro-Q Diamond 
and Sypro Ruby (Fig. 2.5A). Figures 2.5B and 2.5C shows that the relative 
phosphorylation of cTnI and RLC exhibited statistical interactions between 
disease status and cardiac region. In non-failing hearts, the relative 
phosphorylation of cTnI in the RV is ~24% higher than the LV. Conversely, in 
failing preparations, the relative phosphorylation of cTnI in the LV is ~22% more 
than the RV. The largest change in cTnI relative phosphorylation occurred in the 
RV where heart failure produced ~49% reduction (p=0.029, Fig. 2.5B). 
 
 
RLC relative phosphorylation exhibited a similar statistical interaction (Fig 2.5C). 
Mean values were ~40% greater (p=0.041) in samples from non-failing RV than 
in preparations from non-failing LV (p=0.041) whereas RV samples from failing 
hearts had lower relative phosphorylation levels than in preparations from failing 
LV. 
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cMyBP-C relative phosphorylation levels did not demonstrate a significant 
statistical interaction. However, heart failure significantly (p=0.017) reduced the 
relative phosphorylation levels in both chambers (Fig. 2.5D). 
 
 
Ser-23/24 is an important site for cardiac regulation on TnI. Measurements with 
site-specific antibodies (Figs. 2.6A & B) shows a similar statistical interaction 
(p=0.039) to the ProQ diamond cTnI (0.037) relative phosphorylation data (Figs. 
2.5B). 
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Figure 2.2. Heart failure impacts the calcium sensitivity and cooperativity of 
myocardium from the left and right ventricles in different ways. 
A) pCa50 and B) Hill coefficient. Symbols show data for 79 individual preparations 
from n=5 non-failing and n=12 failing hearts. 
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Figure 2.3. Heart failure reduces maximum force and maximum power in 
both ventricles. 
A) Force per cross-sectional area. B) Maximum power output. All data obtained 
in maximally-activating solutions with pCa values of 4.5. Symbols show data for 
79 individual preparations from n=5 non-failing and n=12 failing hearts. 
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Figure 2.4. Shortening velocity and rate of force development are similar 
between the ventricles. 
A) Shortening velocity. B) The rate of tension development, ktr. All data obtained 
in maximally-activating solutions with pCa values of 4.5. Symbols show data for 
79 individual preparations from n=5 non-failing and n=12 failing hearts. 
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Figure 2.5. Myofilament protein phosphorylation in the RV and LV of non- 
failing and failing samples. 
A) Images of representative gels stained with ProQ (left) and SYPRO Ruby 
(right). Symbols show data from 8 failing and 4 non-failing hearts (non-failing 
samples were run in duplicate). Individual bands were normalized to loading 
control. B) Relative phosphorylation of cTnI, C) cMyBP-c, and D) RLC. 
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Fig 2.6. Phosphorylation of TnI Ser 23/24 exhibits a statistical interaction 
between heart failure status and cardiac region. 
A) Representative western blot for TnI Ser-23/24 phosphorylation, and B) total 
TnI. C) Quantification. Gel labels for panels A and B: Marker; molecular weight 
marker, H TnI; purified recombinant human cardiac TnI, M TnI; purified 
recombinant mouse cardiac TnI, M PKA TnI; PKA-treated purified recombinant 
mouse cardiac TnI containing Ser-23/24 phosphorylation. 
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2.4. Discussion 
 
This study shows for the first time that multicellular preparations from the RV and 
LV of human myocardium have similar mechanical properties when maximally 
activated but different sensitivities to activating Ca2+. Intriguingly, in non-failing 
hearts, preparations from the RV are less sensitive to Ca2+ than preparations 
from the LV. In failing hearts, the opposite behavior occurs; RV samples are 
more sensitive to Ca2+. Additional biochemical data suggest that these ventricle- 
specific effects are driven by changes in the relative phosphorylation of cTnI. 
 
 
2.4.1. Mechanical properties of non-failing tissue 
 
One of the long-standing questions in cardiac biology is whether interventricular 
differences in myocardial contraction contribute to the higher systolic pressure 
generated by the LV. To address this question, we measured Fmax, maximum 
power output, and maximum shortening velocity, and rate of tension 
development in non-failing human myocardium from the RV and LV. The data 
show (Figs. 2.3 & 2.4) that none of these parameters exhibited significant inter- 
ventricular differences. 
 
 
To our knowledge, our study is the first to measure these mechanical properties 
using permeabilized human samples. However, Belin et al. 7 and Perreault et al. 
10 had already shown similar Fmax results using permeabilized myocardium from 
rats. Other groups had compared the properties of living (electrically-excitable) 
human tissue. For example, Harding et al. 13 showed that unloaded shortening 
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velocity did not differ between cells from the LV and RV. Together these data 
suggest that myocardium from the LV and RV has similar contractile properties. 
Inter-ventricular differences in pressure are therefore most likely to reflect 
chamber-specific fiber alignments and geometries. 
 
 
2.4.2. Mechanical properties in failing tissue 
 
One of our previous studies showed that end-stage heart failure reduces Fmax 
and maximum power without altering shortening velocity in multicellular 
preparations from the LV of human hearts 95. The biochemical data from that 
study suggested that the reduction in maximal force was most likely to result from 
increased collagen deposition in the failing tissue. In this study, we aimed to test 
if heart failure has a similar impact on the mechanical properties of both 
ventricles. Our data (Figs. 2.3 & 2.4) show that this is indeed the case. Heart 
failure reduced Fmax by ~40% and maximum power out by ~30% in samples from 
both ventricles without changing shortening velocity or ktr. Heart failure thus 
seems to produce similar contractile deficits in both chambers. 
 
 
2.4.3. Calcium sensitivity 
 
To our knowledge, this study is the first to demonstrate that human myocardium 
from the RV and LV has different sensitivities to activating Ca2+. The pCa50 and 
Hill coefficient data both displayed an interaction between disease status and 
cardiac region, with the biggest change in pCa50 and cooperativity occurring 
between the RV of non-failing and failing hearts (Figs 2.2A & B). In non-failing 
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cardiac tissue, pCa50 and Hill coefficient values were higher in the LV. 
Conversely, in failing preparations, the RV had higher pCa50 and Hill coefficient 
values. 
 
 
Our data from non-failing hearts are consistent with prior measurements in rats 
performed by Belin and colleagues 7 and Perreault et al. 10. There are, however, 
some subtle differences between the datasets for failing tissue. Belin et al. 7 
found that heart failure reduced pCa50 in single cells isolated from the LV but had 
no effect on RV cells. Perreault et al. 10 used multicellular preparations and 
demonstrated that heart failure increased pCa50 in RV myocardium but had no 
effect on LV tissue. It is not clear why the three studies produce slightly different 
results, but inter-species effects, differences between single cells and multi- 
cellular preparations, and/or statistical variation could be contributing factors. 
 
 
2.4.4. Phosphorylation of myofilament proteins 
 
It is well known that increased phosphorylation of cTnI (most notably at Ser- 
23/24) reduces myofilament Ca2+ sensitivity 85,86,89,92,99-103. Our data (Figs 2.5B 
and 2.6C) suggest that this modification may be driving the changes we observe 
in pCa50 (Fig 2.2A). All three datasets (pCa50, global cTnI phosphorylation 
assessed with ProQ Diamond, and Ser-23/24 phosphorylation assessed by 
western blot) exhibited statistical interactions between heart failure status and 
cardiac ventricle, with lower pCa50 values (decreased Ca2+ sensitivity) being 
associated with greater cTnI phosphorylation. 
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RLC relative phosphorylation also exhibited a significant statistical interaction 
(Fig 2.5C) with higher phosphorylation levels again being associated with 
reduced Ca2+ sensitivity. This is a more complex relationship because increased 
phosphorylation of RLC is known to enhance Ca2+ sensitivity 104,105. We, 
therefore, think that RLC phosphorylation levels may change in human heart 
failure to compensate for the posttranslational modifications to cTnI partially. 
 
 
This interpretation is similar to that described by van der Velden and coworkers 93 
in their study of end-stage human heart failure. Like us, these authors 
demonstrated parallel changes in the relative phosphorylation of RLC and cTnI. 
They concluded that RLC might be dephosphorylated during human heart failure 
to protect against enhanced Ca2+ sensitivity / diastolic dysfunction resulting from 
dephosphorylation of cTnI. Our data are consistent with this general hypothesis, 
but the molecular mechanisms need to be tested in additional future studies. 
 
 
The data describing cMyBP-C phosphorylation are probably simpler to interpret. 
cMyBP-C was dephosphorylated in failing samples, but there were no inter- 
ventricular effects (Fig 2.5D). Reducing cMyBP-C phosphorylation increases 
myofilament Ca2+ sensitivity 106-109 so this posttranslational modification may be 
driving the global increase in Ca2+-sensitivity observed in the failing samples (Fig 
2.2A). 
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In summary, these biochemical data suggest that changes in cTnI 
phosphorylation are driving inter-ventricular differences in calcium sensitivity 
while dephosphorylation of cMyBP-C contributes to a global increase in pCa50 
values during heart failure. 
 
 
2.4.5. Source of intra-ventricular variation 
 
We do not know why the LV and RV have different Ca2+ sensitivities. They may, 
for instance, be tuned to different mechanical loads. Another possibility is that 
they are responding differently to β-adrenergic stimulation. Molina et al. 110 
showed that the RV was more sensitive to β-adrenergic stimulation than the LV 
in healthy dogs and that the enhanced sympathetic response preferentially 
increased PKA activity in right ventricular tissue. 
 
 
PKA increases phosphorylation of cTnI 111 so differential responses to β- 
adrenergic stimulation could contribute to the inter-ventricular effects that we 
measured for cTnI modifications (Fig 2.5B, 2.6C). However, region-specific 
changes in PKA activity would also be expected to produce enhanced cMyBP-C 
phosphorylation in non-failing myocardium from the right ventricle, which we did 
not observe. Neither is it clear whether human ventricles respond to β-adrenergic 
stimulation in the same way as canine tissue. More experiments in this area are 
required. 
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2.5. Conclusion 
 
This study presents three important results. First, human heart failure increases 
the Ca2+ sensitivity of right ventricular myocardium more than the calcium 
sensitivity of left ventricular myocardium. Second, this contractile effect is likely to 
involve inter-ventricular differences in posttranslational modifications to 
sarcomeric proteins including TnI. Third, heart failure depresses maximum force 
and maximum power by similar amounts in tissue from both ventricles. 
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Chapter 3 
 
Omecamtiv mecarbil increases Ca2+ sensitivity and decreases the rate of 
force development in failing human hearts 
 
 
The content reported in this chapter has been published in “Swenson, A.M., 
Tang, W., Blair, C.A., et al. Omecamtiv Mecarbil Enhances the Duty Ratio of 
Human beta-Cardiac Myosin Resulting in Increased Calcium Sensitivity and 
Slowed Force Development in Cardiac Muscle. The Journal of biological 
chemistry 292, 3768-3778, doi:10.1074/jbc.M116.748780 (2017). PMID 
28082673 112. 
 
 
In this dissertation, only the information about the mechanical analysis from this 
study will be discussed. 
 
 
3.1. Introduction 
 
Heart failure is a clinical syndrome caused by cardiac dysfunction 113. In the 
United States, it affects ~6 million Americans and is the main reason for hospital 
admissions in the elderly 114-116. The most common manifestation of the 
syndrome is systolic heart failure which is marked by decreased contractility 64. 
Many factors can change the function of the heart that can lead to heart failure, 
including cell death, impaired calcium handling, neurohumoral disturbances, and 
changes in cardiac structure (hypertrophy or dilation) 117-119. However, in patients 
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suffering from systolic heart failure, sarcomeric dysfunction plays a central role 
 
75,120. 
 
 
Patients who suffer from systolic heart failure are often prescribed positive 
inotropes to increase contractility and cardiac output. Inotropic drugs are agents 
that enhance myocardial contractile force 121 (Fig. 3.1 50,122). Some of the current 
inotropes used in clinical practice include adrenergic receptor agonist such as 
Norepinephrine, and Dobutamine, as well as the phosphodiesterase inhibitor 
Milrinone 121. At the basic level, an increase in contractile force is accomplished 
by altering actin-myosin interactions. Existing Inotropic agents alter the actin- 
myosin interaction by indirectly activating the secondary messenger signaling 
pathways that increase intracellular Ca2+ concentrations 121. The result of these 
mechanisms is an increase in the number of myosin heads attached to actin 
filaments because of increased Ca2+ binding to troponin C, which increases 
contractile force. While these inotropes increase contractility, unfortunately, they 
also increase heart rate, myocardial oxygen consumption, and can produce 
arrhythmias, all of which can contribute to higher mortality rates 122-124. 
 
To overcome the deleterious effects of current inotropes, drugs that directly 
target the sarcomeres of cardiac tissue are being developed. One class of such 
compounds that directly influence the cross-bridge cycle are called cardiac 
myosin activators 125 (Fig. 3.1 50,122). The first of such drugs that have shown 
signs of overcoming the harmful effects of current inotropes is omecamtiv 
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mecarbil (OM) 124. In studies in dogs 63 and rats 64, OM improved cardiovascular 
function without increasing myocardial oxygen consumption or altering Ca2+ 
transients. Thus, OM is the first cardiac myosin activator that has made it into 
clinical trials 126-128. 
 
For sarcomeres to generate force, actin and myosin must interact 129. During the 
actin-myosin cross-bridge cycle, actin and myosin undergo weak and strong 
binding (Fig.3.2 62). The cycle is initiated by the binding of ATP to myosin which 
allows myosin to dissociate from actin rapidly. The rapid hydrolysis of ATP to 
ADP and Pi by the ATPase of the cross-bridges (S1 in Fig 3.1) creates a weak or 
electrostatic contact between actin and myosin. Upon binding, the newly formed 
actin-myosin-ADP-Pi complex undergoes an activation step which concomitantly 
involves the release of Pi and the transition of actin and myosin from a weakly- 
bound to a strongly-bound state (Fig. 3.2 62) 130. It is also during the release of Pi 
were the cross-bridges undergo a conformational change producing a ~10 nm 
power-stroke which contracts the muscle. The transition from the weak to 
strongly bound state between actin and myosin is a critical step, as it dictates the 
amount of force the muscle will be able to produce 131,132. OM accelerates this 
transition, as the drug increases the rate of phosphate release (Fig. 3.2 62) 
forcing actin and myosin into the strong force producing state faster 64,133,134. 
Thus, OM enhances the number of myosin heads in the strongly-bound force 
generating state at any given time during the cross-bridge cycle, which increases 
the amounts of cross-bridges pulling on actin. 
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The impact of OM on cardiac function in a dose-dependent manner in humans 
has not been studied. This study aims to test the hypothesis that OM alters the 
mechanical properties of permeabilized human cardiac tissue in a dose- 
dependent manner. 
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Figure 3.1. Selected inotropes mode of action 
 
Figure was made by combining and modifying figures from Hwang & Sykes, 
2015 50  and Tarone et al., 2014 122 
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Figure 3.2. Actin-Myosin cross-bridge cycle illustrating the segment of the 
cycle (between 3a and 3b) omecamtiv mecarbil is proposed to influence 
Figure modified from James Spudich, 2014 62 
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3.2. Methods 
 
The human cardiac samples used for this study were procured as described in 
the methods section of chapter 2, section 2.2.1. 
 
 
3.2.1. Clinical characteristics of patients with heart failure 
 
The samples from patients undergoing heart transplants came from 3 males 
(classification of heart failure: 2 ischemic and 1 non-ischemic) and 5 females 
(classification of heart failure: 1 ischemic and 4 non-ischemic). The mean age of 
the patients was 50 (range 31 to 68). Patients’ characteristics are summarized in 
table 3.1. 
 
 
3.2.2. Multicellular preparations 
 
Permeabilization of human tissue was performed as described in section 2.2.3. A 
total of 46 multicellular preparations from 8 patients with heart failure were 
analyzed. The average length of the preparations used in this study was 1055 ± 
229 µm, and the average cross-sectional area was 5.87 ± 2.42 x 10-8 m2. Cross- 
sectional area was estimated assuming a circular profile. 
 
 
3.2.3. Incubation of multicellular preparations 
 
Solutions with pCa values ranging from 9.0 to 4.5 (made as described in the 
methods section of chapter 2, section 2.2.5) and OM concentrations of 0.1, 1.0, 
or 10 µM were made by adding suitable amounts of OM dissolved in DMSO. The 
final percentage of DMSO in every experimental solution was 0.67%. 
64  
Preparations were immersed in a pCa 9.0 solution containing 0 (control), 0.1, 1.0, 
or 10.0 µM for at least 3 min between trials. The ionic strength was held constant 
at 180 mM in all solutions. 
 
 
3.2.4. Mechanical measurements 
 
Pilot test showed that OM is hard to wash out of the multicellular preparations. 
Each preparation was therefore exposed to only one concentration of OM (0, 0.1, 
1.0, or 10 µM). All experimental measurements were conducted at 15°C using 
the experimental set-up describes in section 2.2.4 and SLControl software 96. For 
this study only maximum force, the rate of tension development, and Ca2+ 
sensitivity as described in section 2.2.6 were measured. Shortening velocity and 
maximum power measurements were not performed in this study. The higher 
concentrations of OM (1.0 and 10 µM) altered the natural properties of 
multicellular preparations so these measurements could not be done with 
accuracy. 
 
 
3.2.5. Statistical analysis 
 
A linear mixed model approach that took into account drug concentration and 
multiple preparations from the same patient was used to analyze 46 multicellular 
preparations from 8 patients. 
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Table 3.1. Patients’ characteristics  
Age Gender Diagnosis Cardiomyopathy 
56 Female Failing Non-ischemic 
36 Female Failing Noon-ischemic 
59 Female Failing Ischemic 
31 Female Failing Non-ischemic 
66 Female Failing Non-ischemic 
37 Male Failing Ischemic 
68 Male Failing Ischemic 
47 Male Failing Non-ischemic 
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3.3. Results 
 
3.3.1. OM increases Ca2+ sensitivity and decreases the rate of force 
development 
The effects of OM on the mechanical properties of human myocardium were 
measured using chemically permeabilized multicellular preparations. The 
maximum isometric force was not significantly altered by OM (Fig. 3.3). In 
contrast, 1 and 10 µM OM significantly (p<0.001) increased pCa50 (Fig. 3.4). In 
comparison to vehicle, 1 µM OM increased pCa50 from 5.55 ± 0.06 to 5.83 ± 0.08 
(p<0.001), while 10 µM OM increased pCa50 from 5.55 ± 0.06 to 6.05 ± 0.18 
((p<0.001). These concentrations of OM also slowed ktr, the rate of force 
development (ktr in OM-free medium: 1.04 ± 0.26 s-1; in 1 µM OM: 0.33 ± 0.11 s-1 
(p<0.001 vs OM free medium); in 10 µM OM 0.17 ± 0.16 s-1 (p<0.001 vs OM free 
medium)) (Fig. 3.5). 
67  
 
 
Figure 3.3. OM does not alter maximum force 
All data obtained in maximally-activating solutions with pCa values of 4.5. 
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Figure 3.4. OM increases Ca2+ sensitivity in a dose-dependent manner 
 
All data obtained in maximally-activating solutions with pCa values of 4.5. 
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Figure 3.5. OM decreases the rate of force development 
 
All data obtained in maximally-activating solutions with pCa values of 4.5. 
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3.4. Discussion 
The impact of omecamtiv mecarbil on the mechanical properties of permeabilized 
cardiac tissue has been studied in rats 135 and humans 136. In rats, OM increased 
calcium sensitivity, slowed the rate of force development, and enhanced force in 
sub-maximal calcium concentrations 135. Mamidi et al. 136 performed similar 
measurements in humans, using 1 µM OM in sub-maximal calcium 
concentrations. They reported that OM increased isometric force and calcium 
sensitivity. Our study adds to the findings of Mamidi and coworkers 136 by further 
examining the impact of OM on human myocardium in a dose-dependent 
manner. We find an increase in calcium sensitivity in a dose-dependent manner 
with little change in steady-state force at maximum calcium concentrations. Also, 
we observe a decrease in the rate of force development. 
 
 
The fraction of cross-bridges bound to actin in the strongly bound state at any 
moment during the actin-myosin ATPase cycle is referred to as the “duty ratio” 
137. By increasing the duty ratio, you increase cooperative activation of the thin 
filament making it more sensitive to calcium 138,139. Additionally, an increase in the 
duty ratio could reduce the rate of force development by slowing the detachment 
of strongly-bound myosin heads from actin. To determine if OM increased the 
duty ratio, in vitro motility assays were performed (not included in the 
dissertation, but was done by collaborator for manuscript). The results of the in 
vitro motility assays showed that OM increased the duty ratio, and trapped a 
population of myosin heads in a weakly-bound state with actin, slowing 
phosphate release 112. Thus, we propose that OM increases calcium sensitivity 
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by increasing the duty ratio. Additionally, the data suggest that the reduction in 
the rate of force development could be the result of the increase in weakly bound 
non-force generating cross-bridges, or because of the increase in the duty ratio, 
which would slow the detachment of cross-bridges. 
 
 
Shortening velocity measurements were attempted in the mechanical 
measurements. However, at OM concentrations of 1 and 10 µM, shortening 
velocity measurements could not be accurately obtained with the multicellular 
preparations. The drug drastically reduced force development; thus, when 
performing the load clamps (changing the length of the preparation), an accurate 
measurement of the force generated by multicellular preparation could not be 
obtained. Therefore, shortening velocity measurements were not recorded. 
However, sliding velocity measurements were performed by our collaborators. 
Using in vitro motility assays, they were able to measure the sliding velocity of 
actin with the same human cardiac samples used for the multicellular preparation 
experiments (all of these data are published in the manuscript by Swenson et al. 
112). Similar to the rate of force development, the results of the motility assay 
showed that OM significantly reduced sliding velocity 112. These findings are 
consistent with earlier studies in pigs 140,141 and humans 142. From the results of 
the motility assays, it was proposed that in the presence of OM a population of 
myosin heads is consistently cycling from a detached to a weakly-bound state 
with actin, which slows phosphate release creating a viscous drag that reduces 
the actin sliding velocity. 
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3.5. Summary 
 
The discovery of omecamtiv mecarbil as an inotrope that can alter contractile 
properties without changing calcium homeostasis and myocardial oxygen 
consumption is promising for patients suffering from systolic heart failure. The 
drug has made it into clinical trials. A phase I trial demonstrated an improvement 
in systolic ejection time and stroke volume 126. Similarly, a phase II trial also 
showed increased systolic ejection time 143. Both studies reported that the effects 
are dose-dependent. Overall, it appears that dosing could be critical to receive 
the maximum benefits of the drug. The findings of this and previous studies also 
would suggest that an appropriate dose of OM is essential, as too much of the 
drug can slow force development and increase calcium sensitivity, which may 
impact the rate of relaxation. 
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Chapter 4 
Para-Nitroblebbistatin reduces maximum force and calcium sensitivity in 
human myocardium 
 
The effects of para-Nitroblebbistatin on the mechanical function of human 
myocardium are published in, Tang, W., Blair, C.A., et al. Modulating Beta- 
Cardiac Myosin Function at the Molecular and Tissue Levels. Frontiers in 
Physiology 7, doi:10.3389/fphys.2016.00659 (2017). PMID: 28119616 144. 
 
In this dissertation, only the information about the mechanical analysis from this 
manuscript will be discussed. 
 
4.1. Introduction 
Hypertrophic cardiomyopathy (HCM) is the most common occurring inherited 
cardiac disease 145. Clinically, HCM is characterized by hypertrophy of the 
ventricles and interventricular septum in the absence of predisposing conditions 
such as hypertension or aortic stenosis 146. Consequently, the interior diameters 
of the chambers decrease, ventricular compliance is reduced, and diastolic 
function is impaired 147. Pathologically, HCM results in disarrayed 
cardiomyocytes and increased fibrosis 148. The disease is prevalent, as 1 in 500 
individuals are affected by HCM which may result in heart failure or sudden death 
149. 
 
 
HCM is a disease of the sarcomere, as up to 60 to 70% of HCM cases are 
attributed to mutations in sarcomeric proteins 150-152. Defects in genes encoding 
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myosin heavy chain 153, myosin essential 154 and regulatory light chains 155, 
myosin-binding protein C 156, actin 157, tropomyosin 158, troponins I 159, C 160 and 
T 161 have all been associated with HCM. The most common being mutations in 
the human β-cardiac myosin heavy chain, which accounts for ~40% of HCM 
cases 162,163. Within the entire human β-cardiac myosin (heavy and light chains), 
there have been over 300 pathogenic mutations described, most of which are in 
the motor (subfragment 1 (S1)/cross-bridges) domain 164-166. 
 
Human β-cardiac myosin is the motor that drives contraction. Studies have 
shown that mutations in this protein can make the heart hypercontractile 167,168. 
At the mechanical level, a hypercontractile heart generates more power (product 
of force and velocity). Thus, patients suffering from HCM as a result of myosin 
mutations often exhibit hyperdynamic (substantially high ejection fraction) 
ventricular function 169. Currently, there is no pharmacological therapy for HCM. 
However, small molecules that can reduce the amount of force (i.e., reduce 
power) by lowering the duty ratio (fraction of cross-bridges bound to actin in the 
strongly bound state at any moment during the ATPase cycle) has the potential 
to help patients suffering from HCM with hyperdynamic ventricular function. 
 
 
Blebbistatin is a small molecule used as an experimental tool to inhibit myosin 
function 170,171. The molecule was first identified as a non-muscle myosin II 
specific inhibitor but has seen been shown to inhibit myosin in striated muscle as 
well 65,172. Blebbistatin inhibits the force generating capacity of myosin by 
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specifically binding to the myosin-ADP-Pi complex which slows the release of 
inorganic phosphate, trapping cross-bridges in the weakly bound state with actin 
(Fig. 4.1 62) 170-172. Additionally, studies have shown that Blebbistatin can reduce 
the amount of force cardiac tissue produce by stabilizing the binding of myosin 
heads to the thick filament 173-175, thus removing the ability of cross-bridges to 
interact with actin. The folding of myosin heads where they cannot interact with 
the thin filament is referred to as the super-relaxed state 176. The mechanism by 
which Blebbistatin anchors myosin heads to thick filaments is unknown 175. In 
rodents, the effects of Blebbistatin were shown to be dose-dependent, as Dou et 
al. 177 demonstrated that mice given different doses of Blebbistatin decreased 
twitch force and shortening velocity in a dose-dependent manner. 
 
 
In its general form, the use of Blebbistatin as an experimental tool is hindered, as 
blue-light exposure reverses it inhibitory effects 178. Additionally, the molecule is 
cytotoxic, phototoxic, and has poor solubility 179. To address these issues, more 
soluble, non-cytotoxic, non-phototoxic, non-fluorescent derivatives called para- 
NitroBlebbistatin (pN-Bleb) and para-amino-blebbistatin has been synthesized 
180,181. These derivatives exhibit the same myosin inhibitory effects. 
 
This study aimed to test the hypothesis that pN-Bleb will alter the mechanical 
properties of human cardiac tissue from patients with heart failure. The results of 
our study show that pN-Bleb reduces maximum force, power, and calcium 
sensitivity without altering shortening velocity or the rate of tension development. 
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These data provide evidence that drugs designed to reduce myosin duty ratio by 
inhibiting strong attachment to actin can potentially treat patients with HCM. 
 
 
4.2. Methods 
 
The human cardiac samples used for this study were procured as described in 
the methods section of chapter 2, section 2.2.1. 
 
 
4.2.1. Clinical characteristics of patients with heart failure 
 
The samples from patients undergoing heart transplantation came from 2 males 
(classification of heart failure: 1 ischemic and 1 non-ischemic) and 2 females 
(classification of heart failure: 2 non-ischemic). The mean age of the patients was 
45 (range 31 to 68). Patients’ characteristics are summarized in Table 4.1. 
 
 
4.2.2. Multicellular preparations 
 
Permeabilization of human tissue was performed as described in section 2.2.3. A 
total of 46 multicellular preparations from 8 patients with heart failure were 
analyzed. The average length of the preparations used in this study was 1047 ± 
232 µm, and the average cross-sectional area was 5.07 ± 2.47 x 10-8 m2. Cross- 
sectional area was estimated assuming a circular profile. 
 
 
4.2.3. Solutions 
 
The ionic composition of the pCa solutions used in this study was adjusted for 
use at 22° C. The ionic strength was held constant at 180 mM in all solutions. 
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The relaxing solution used to isolate and permeabilize multicellular preparations 
did not change from what was described in chapter 2, section 2.2.5. To make the 
pCa solutions, we initially made pCa 4.5 & 9.0. Those two pCa solutions were 
then mixed to make intermediate concentrations ranging from pCa 5.0 to pCa 
6.4. The composition of pCa 4.5 (mmol L-1): 7 EGTA, 20 Imidazole, 51 KCL, 14.5 
Creatine, 4.8 ATP, 7 CaCl2, 5.22 mgCl2, sufficient amounts of KOH to get pH to 
7.0. The composition of pCa 9.0 (in mmol L-1): 7 EGTA, 20 Imidazole, 68 KCL, 
 
14.5 Creatine phosphate, 4.74 ATP, 5.48 MgCl2, and 15.3 µM CaCl2 plus ample 
amount of KOH to reach pH 7.0. 
 
 
4.2.4. Incubation of samples with pN-Bleb 
 
pN-Bleb combined with Dimethyl sulfoxide (DMSO) was added to pCa values 
ranging from 9.0 to 4.5 to create solutions with a final concentration of 0 (DMSO 
only), 1,10, or 50 μM pN-Bleb. The final percentage of DMSO in every 
experimental solution was 1.33%. Each preparation was initially tested in control 
solutions (0 pN-Bleb) with pCa values ranging from 9.0 to 4.5. The preparation 
was then immersed for 5 min in a pCa 9.0 solution containing 1, 10, or 50 μM pN- 
Bleb. Mechanical experiments described in sections 2.2.6 and 2.2.7 were then 
performed to assess maximum force, calcium sensitivity, the rate of force 
development, shortening velocity and maximum power. These samples were 
only tested in pCa 4.5 solutions with 0 pN-Bleb(control) and then a chosen 
experimental pN-Bleb concentration. These experimental designs ensured that 
each preparation could act as its own control and minimized the progressive 
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decline in contractile force (experimental run-down) that occurs when 
permeabilized preparations are subjected to repeated activations. 
 
 
4.2.5. Statistical analysis 
 
The same linear mixed model used in section 3.2.5 was used to analyze the 24 
multicellular preparations from the 4 patients used in this study. 
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Figure 4.1. pN-Blebb mode of action 
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Table 4.1. Patients’ characteristics  
Age Gender Diagnosis Cardiomyopathy 
36 Female Failing Non-ischemic 
31 Female Failing Non-ischemic 
68 Male Failing Ischemic 
47 Male Failing Non-ischemic 
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4.3. Results 
 
4.3.1. pN-Bleb reduces maximum force and power 
 
To assess the impact of pN-Bleb on the mechanical function of permeabilized 
human hearts, I measured force, tension recovery, Ca2+ sensitivity, shortening 
velocity and power in maximum Ca2+ solution containing either control (DMSO 
only), 1, 10, or 50 µM pN-Bleb. Figure 4.2 shows the maximum force and 
maximum power of 1, 10 and 50 µM pN-Bleb normalized to control. Maximum 
force (Fig. 4.2A) was significantly different (p=0.020) between the 1 µM and 50 
µm pN-Bleb. The maximum power generated by the preparations were 
significantly reduced at 50 µM (p<0.001) and 10 µM (p=0.024) pN-Bleb (Fig. 
4.2B). Neither maximum shortening velocity (Fig. 4.3A) or rate of tension 
recovery (ktr) (Fig. 4.3B) changed between the varying concentrations of pN- 
Bleb. 
 
 
Figure 4.4A shows tension-pCa curves of 1, 10 and 50 µM pN-Bleb normalized to 
control. The curves indicate that in addition to reducing relative force, pN-Bleb 
also reduced Ca2+ sensitivity (pCa50  values; Fig. 4.4B) and the Hill coefficient 
(Fig. 4.4C). The effects of pN-Bleb on pCa50 and the Hill coefficient were only 
significant at the 50 µM concentration. 
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Figure 4.2. pN-Bleb reduced maximum force and maximum power.  
The left- hand panels show data measured in pCa 4.5 solution plus 1.33% 
DMSO. Right- hand panels show data measured in pCa 4.5 solution plus 1.33% 
DMSO and either 1, 10, or 50 µM pN-Bleb. The different concentrations of pN-
Bleb were normalized to the control (DMSO only). A) Maximum force, and B) 
maximum power. 
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Figure 4.3. pN-Bleb does not alter shortening velocity or the rate of tension 
recovery.  
The left-hand panels show data measured in pCa 4.5 solution plus 1.33% 
DMSO. Right-hand panels show data measured in pCa 4.5 solution plus 1.33% 
DMSO and either 1, 10, or 50 µM pN-Bleb. The different concentrations of pN-
Bleb were normalized to the control (DMSO only). A) Maximum shortening 
velocity, and B) rate of tension redevelopment. 
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Figure 4.4. Impact of pN-Bleb on Ca2+ sensitivity and isometric force.  
A) Representative tension-pCa curves for multicellular preparations activated in 
solutions with pCa values ranging from 9.0 to 4.5. The control (gray) data points 
show force values measured in the presence of 1.33% DMSO. The red, green, 
and blue data points show force measured in 1.33% DMSO plus 1, 10, or 50 µM 
pN-Bleb. All force values were normalized to the control. B) pCa50 and C) Hill 
coefficient results. 
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4.4. Discussion 
HCM is an inherited disease that can lead to a hypercontractile heart. Currently, 
there is no effective treatment for the disease. However, small molecules may 
serve as therapy to treat the disorder, as these compounds can regulate human 
beta myosin, the primary protein driving the hypercontractile phenotype seen in 
HCM patients. Utilizing a modified version of the myosin inhibitor blebbistatin, the 
findings of this study suggest that small molecules designed to target human 
hearts with myosin inhibitory capacity similar to that of blebbistatin may serve as 
therapy for patients suffering from HCM. The results of the current research show 
that pN-Bleb reduces maximum force, maximum power, and alter Ca2+ sensitivity 
without changing the rate of cell shortening or tension recovery in human 
myocardium. 
 
 
While the interpretation of the force and power data is unambiguous, caution 
should be taken when interpreting the pCa50 and Hill coefficient data. As shown 
in figure 4.4, the pCa50 (Fig. 4.4B) and Hill coefficient (Fig. 4.4C) values 
significantly decreased in the 50 µM pN-Bleb concentrations but did not 
demonstrate any marked effects in the 1 or 10 µM concentrations. A possible 
explanation for the reduction in pCa50 and Hill coefficients at 50 µM pN-Bleb 
concentrations could be the absence of the flat plateau in the tension-pCa curve 
at 50 µM. The absence of the flat plateau would suggest that isometric force did 
not completely saturate in a pCa 4.5 solution in the presence of 50 µM pN-Bleb. 
These data could indicate that a high concentration of pN-Bleb desensitizes the 
thin filaments by reducing the myosin duty ratio which would lower pCa50 and Hill 
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coefficient values. Additionally, the low Hill coefficients and pCa50 values 
measured in the presence of 50 µM pN-Bleb may also be explained by a 
progressive reduction in force development during the experiments. In rodent 
hearts, Dou et al. 177 showed that the effects of blebbistatin on force development 
are time-sensitive, as it took ~30 min for the force to stabilize in the presence of 
the drug. It is possible that similar time-dependent effects in human myocardium 
might produce tension-pCa data similar to those shown in Figure 4.4A. 
 
 
In the multicellular preparations, shortening velocity did not significantly vary 
between the pN-Bleb concentrations. However, it is worth noting that sliding 
velocity of S1 sub-fragment of myosin heads decreased in the in-vitro motility 
assays (data not shown here, published in Tang, Blair...et al 144) exposed to the 
same concentrations of pN-Bleb as in the human mechanics study. In the motility 
assay, pN-Bleb reduced sliding velocity in a concentration-dependent manner. 
These data suggest that differences observed in sliding velocity at the molecular 
level do not translate to the tissue level. However, these differences between the 
molecular and tissue level may reflect the structural organization of the myosin 
heads at the tissue level. Within the tissue, there are many myosin heads near 
actin filaments, whereas in the motility assay not as many heads are interacting 
with actin filaments. Thus, the lowered sliding velocity observed at the molecular 
level could reflect the sensitivity of smaller amounts of heads to pN-Bleb 
inhibition that is not present in the larger organized tissue. To support this 
hypothesis, Fusi et al. 182 showed that only 1-4 myosin heads per thick filament 
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are required to sustain maximum shortening velocity in muscle fibers. Thus, even 
though some heads may be experiencing pN-Bleb effects in the tissue, there are 
enough heads that are not undergoing inhibition to maintain shortening velocity. 
 
 
The use of small molecules that target the contractile apparatus to treat cardiac 
dysfunction has garnered a lot of attention, as some of these molecules have 
shown promise and have made it into clinical trials. For example, the 
aforementioned omecamtiv mecarbil (studies in chapter 3), and more recently, 
MYK-461. Similar to pN-Bleb, MYK-461 reduces the rate of phosphate release in 
the actin-myosin ATPase cycle. A recent study suggests that MYK-461 can 
diminish the hypercontractile nature of HCM hearts by reducing the myosin duty 
rate, thus decreasing the force and power 183. These findings were demonstrated 
in rodent hearts. The results reported in this dissertation and the manuscript 
published by Tang, Blair, et al., 144 would suggest that MYK-461 should have 
similar effects in humans, as the mode of action of both molecules is similar. The 
findings of this study and the use of MYK-461 in rodents to treat HCM are 
exciting, as they provide evidence that small molecules can potentially be used to 
treat patients with who suffer from HCM. However, more research is needed to 
see how effective compounds like MYK-461 are in patients with a variety of HCM 
mutations. 
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Chapter 5 
Engineered troponins modulate the Ca2+ sensitivity of the 
failing human myocardium 
5.1. Introduction 
The troponin complex is a primary regulator of cardiac muscle contraction and 
relaxation. It consists of troponin C (TnC) the Ca2+  binding subunit, troponin I 
(TnI) the inhibitory subunit, and troponin T (TnT) the tropomyosin binding subunit. 
For a muscle to contract, free Ca2+ ions must bind TnC, which releases the 
inhibitory effects of TnI leading to a conformational shift in TnT, a cascade that 
ultimately enables the interaction of actin and myosin. Contrarily, the removal of 
Ca2+ ions from TnC must occur for actin and myosin to dissociate and relax the 
muscle. Being the Ca2+ sensor, TnC plays an integral role in tuning the response 
of the myofilament to Ca2+. However, the response of TnC to Ca2+ can be 
potentiated or reduced by other myofilament proteins (TnI, TnT, tropomyosin, 
and myosin) and by posttranslational modifications to many of these proteins 184- 
186. 
 
Myofilament calcium sensitivity is a concept researcher use to describe the 
relationship between the concentration of free Ca2+ ions available to bind TnC 
and the amount of force the muscle generates 187. While this reductionist 
approach reduces a complex system to two variables: free Ca2+ ions and force of 
contraction, it has provided significant insights into the mechanisms that govern 
cardiac contractility. Typically, hearts with increased Ca2+ sensitivity are 
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associated with increased contractility, whereas myofilaments that are less 
sensitive to Ca2+ have reduced contractility 187. 
 
A common observation in samples from patients with hypertrophic and dilated 
cardiomyopathy, as well as systolic and diastolic heart failure, is aberrant 
myofilament Ca2+ sensitivity 188-192. Although it is unclear the exact mechanism by 
which Ca2+ sensitivity contributes to these etiologies, it is clear from studies in 
rodents that correcting cardiac Ca2+ sensitivity through genetic manipulation of 
myofilament proteins can restore normal myofilament Ca2+ sensitivities 193. 
Specifically, Liu et al. 193 using permeabilized tissue showed that TnC engineered 
to either increase or decrease Ca2+ sensitivity in rodent hearts with restrictive 
(increased Ca2+ sensitivity) or dilated (decreased Ca2+ sensitivity) 
cardiomyopathic mutations can restore normal Ca2+ sensitivity. Additionally, 
Shettigar and coworkers 194 recently demonstrated that rationally engineered 
troponins could be delivered in-vivo to correct and enhance cardiac function in a 
rodent model. 
 
 
Rodent models have shown that there are many ways to modulate the Ca2+ 
sensitivities of cardiac muscle. However, it is unclear how engineered proteins 
can alter Ca2+ sensitivities in human myocardium. In this study, engineered TnCs 
and TnIs (Fig 5.1) were exchanged into the permeabilized human myocardium to 
either increase or decrease myofilament Ca2+ sensitivity. The results show that 
compared to the wild-type troponins, our Ca2+ sensitizing L48Q TnC and S150D 
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TnI troponins exchanges both increased pCa50. Conversely, the Ca2+ 
desensitizing D73N TnC and Y26E TnI troponins exchanges both decreased 
Ca2+ sensitivity. In the presence of saturating Ca2+, the maximal force per cross- 
sectional area, shortening velocity, the rate of tension redevelopment (ktr) and 
power were all similar for the exchanged troponins suggesting the modified 
troponins have a negligible direct impact on myosin function. This study 
demonstrates that the myofilament responsiveness of the failing human heart to 
Ca2+ can be modulated by engineering either TnC or TnI. These findings open 
the door to potential new troponin targeted therapies for heart disease. 
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Figure 5.1. Ribbon representation of troponin complex with TnC and TnI 
mutations used in this study 
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5.2. Methods 
The human cardiac samples used for this study were procured as described in 
the methods section of chapter 2, section 2.2.1. 
 
 
5.2.1. Clinical characteristics of patients with heart failure 
 
The samples from patients undergoing heart transplantation came from 3 
females (classification of heart failure: 3 non-ischemic). The mean age of the 
patients was 48 (range 31 to 65). Patients’ characteristics are summarized in 
Table 5.1. 
 
 
5.2.2. Multicellular preparations 
 
Permeabilization of human tissue was performed as described in section 2.2.3. A 
total of 18 multicellular preparations from 3 patients with heart failure were 
analyzed. The average length of the preparations used in this study was 973 ± 
138 µm, and the average cross-sectional area was 4.97 ± 2.35 x 10-8 m2. Cross- 
sectional area was estimated assuming a circular profile. 
 
 
5.2.3. Solutions 
 
The ionic composition of the pCa solutions used in this study was adjusted for 
use at 22° C. The ionic strength was held constant at 180 mM in all solutions. 
The relaxing solution used to isolate and permeabilize multicellular preparations 
did not change from what was described in chapter 2, section 2.2.5. To make the 
pCa solutions, we initially made pCa 4.5 & 9.0. Those two pCa solutions were 
then mixed to make intermediate concentrations ranging from pCa 5.0 to pCa 
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6.4. The composition of pCa 4.5 (mmol L-1): 7 EGTA, 20 Imidazole, 51 KCL, 14.5 
Creatine, 4.8 ATP, 7 CaCl2, 5.22 mgCl2, sufficient amounts of KOH to get pH to 
7.0. The composition of pCa 9.0 (in mmol L-1): 7 EGTA, 20 Imidazole, 68 KCL, 
 
14.5 Creatine phosphate, 4.74 ATP, 5.48 MgCl2, and 15.3 µM CaCl2 plus ample 
amount of KOH to reach pH 7.0. 
 
 
5.2.4. Incubation of samples with engineered troponins 
 
The engineered troponins used in this study were sent to us from our 
collaborators at the Ohio State University. Including wild-type, there were five 
troponin complexes used in this study. The constructs of each troponin complex 
have in the abbreviation “Hc” for human cardiac, “Tn” for troponin, and either 
“WT” for wild-type,” or a letter with a number and another letter representing the 
amino acid substitution for either TnC or TnI. The constructs are as followed: 
• HcTn WT (Human cardiac troponin containing TnT WT with a Myc Tag / TnC 
 
WT / TnI WT) at 10uM 
 
• HcTn L48Q (Human cardiac troponin containing TnT WT with a Myc Tag / 
 
TnC with L48Q mutation +IAANS / TnI WT) at 11uM 
 
• HcTn D73N (Human cardiac troponin containing TnT WT with a Myc Tag / 
 
TnC with L48Q mutation / TnI WT) at 11uM 
 
• HcTn S150D (Human cardiac troponin containing TnT WT with a Myc Tag / 
 
TnC WT / TnI Ser-150 with Asp pseudophos) at 11uM 
 
• HcTn Y26E (Human cardiac troponin containing TnT WT with a Myc Tag / 
 
TnC WT / TnI Tyr-26 with Glu pseudophos) at 11uM 
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All troponin complexes contain TnC with the fluorescent labeled T53C mutation 
that does not alter function and was in Exchange buffer (0.2M KCl, 5mM MgCl2, 
5mM EGTA, 1mM DTT, 20mM MOPS, pH 6.5). 
 
 
To exchange the engineered troponin complexes with the native troponin 
complexes, two to three permeabilized preparations were placed in one of the 
wells in a 96 well microtiter plate. The preps were then incubated for 24-hours 
with 100 µL of one of the five troponin constructs at 4°C. The next day; the 
preparations were then removed from the plate to carry out the mechanical 
experiments described in sections 2.2.6 and 2.2.7. 
 
 
5.2.5. Statistical analysis 
 
The same linear mixed model used in section 3.2.5 was used to analyze the 18 
multicellular preparations from the 3 patients used in this study. 
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Table 5.1. Patients’ characteristics  
Age Gender Diagnosis Cardiomyopathy 
65 Female Failing Non-ischemic 
31 Female Failing Non-ischemic 
50 Female Failing Non-ischemic 
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5.3. Results 
The results of the troponin exchange (Fig 5.2) shows that on average the 
engineered troponins replaced ~80% of the native troponins in the multicellular 
preparations, none of which significantly differed from the other (% exchange: 
hTnC WT = 73.2 ± 15.8, hTnC L48Q = 84.7 ± 8.9, hTnC D73N = 80.0 ± 15.4, 
cTnI S150D = 79.3 ± 11.9, cTnI Y26E = 84.8 ± 9.3; p > 0.05). Additionally, the 
Ca2+ sensitivity data (Fig 5.3) demonstrates that in comparison to wild-type, the 
Ca2+  sensitizing L48Q TnC and S150D TnI both increased (p<0.001) pCa50 from 
~5.48 to 5.84 and ~5.68, respectively. Conversely, the Ca2+desensitizing D73N 
TnC and Y26E TnI both decreased (p<0.001) pCa50 to ~5.05 and ~5.29, 
respectively. The Hill coefficient data also demonstrated a significant (p=0.015) 
difference, which further post-hoc analysis shows is driven by the reduction in the 
Hill coefficient from ~2 to ~1 in preparations containing the TnC L48Q troponin 
complex (Fig 5.4). Either of the troponins had any significant impact on maximum 
force (Fig 5.5), maximum power (Fig 5.6), maximum shortening velocity (Fig 5.7), 
or the rate of tension recovery (Fig 5.8). 
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Figure 5.2. Percentage of engineered troponins exchanged into 
multicellular preparations from human myocardium.  
Left) Western blot of TnT with Myc-tag and endogenous TnT to distinguish 
exchanged troponin complexes from endogenous complexes. Right) 
Quantification of troponin exchange. WT = Wild-type; L48Q = TnC Ca2+ 
sensitizing mutation; D73N = TnC Ca2+ desensitizing mutation; S150D = TnI 
Ca2+ sensitizing mutation; Y26E = TnI Ca2+ desensitizing mutation. HcTnT = 
human cardiac TnT; HcTnT-myc = human cardiac TnT with Myc-tag 
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Figure 5.3. Tension-pCa curve of engineered troponins. Error bars are 
displayed on shapes that had multiple data points for that given pCa value. 
WT = Wild-type; L48Q = TnC Ca2+ sensitizing mutation; D73N = TnC Ca2+ 
desensitizing mutation; S150D = TnI Ca2+ sensitizing mutation; Y26E = TnI Ca2+ 
desensitizing mutation 
99  
 
Figure 5.4. Engineered troponins can alter Ca2+ sensitivity in human 
myocardium.  
Data points represent individual multicellular preparation from n=3 patients, 
measurements were repeated for WT. WT = Wild-type; L48Q = TnC Ca2+ 
sensitizing mutation; D73N = TnC Ca2+ desensitizing mutation; S150D = TnI Ca2+ 
sensitizing mutation; Y26E = TnI Ca2+ desensitizing mutation 
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Figure 5.5. Ca2+ sensitizing TnC L48Q lowers Hill coefficient.  
Data points represent individual multicellular preparation from n=3 patients, 
measurements were repeated for WT. WT = Wild-type; L48Q = TnC Ca2+ 
sensitizing mutation; D73N = TnC Ca2+ desensitizing mutation; S150D = TnI Ca2+ 
sensitizing mutation; Y26E = TnI Ca2+ desensitizing mutation 
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Figure 5.6. Engineered troponins does not alter maximum isometric force. 
Data points represent individual multicellular preparation from n=3 patients, 
measurements were repeated for WT. WT = Wild-type; L48Q = TnC Ca2+ 
sensitizing mutation; D73N = TnC Ca2+ desensitizing mutation; S150D = TnI Ca2+ 
sensitizing mutation; Y26E = TnI Ca2+ desensitizing mutation 
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Figure 5.7. Engineered troponins do not alter maximum power.  
Data points represent individual multicellular preparation from n=3 patients, 
measurements were repeated for WT. WT = Wild-type; L48Q = TnC Ca2+ 
sensitizing mutation; D73N = TnC Ca2+ desensitizing mutation; S150D = TnI Ca2+ 
sensitizing mutation; Y26E = TnI Ca2+ desensitizing mutation 
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Figure 5.8. Engineered troponins do not alter maximum shortening 
velocity.  
Data points represent individual multicellular preparation from n=3 patients, 
measurements were repeated for WT. WT = Wild-type; L48Q = TnC Ca2+ 
sensitizing mutation; D73N = TnC Ca2+ desensitizing mutation; S150D = TnI Ca2+ 
sensitizing mutation; Y26E = TnI Ca2+ desensitizing mutation 
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Figure 5.9. Engineered troponins do not alter the rate of force development, 
ktr.  
Data points represent individual multicellular preparation from n=3 patients, 
measurements were repeated for WT. WT = Wild-type; L48Q = TnC Ca2+ 
sensitizing mutation; D73N = TnC Ca2+ desensitizing mutation; S150D = TnI Ca2+ 
sensitizing mutation; Y26E = TnI Ca2+ desensitizing mutation 
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5.4 Discussion 
 
Unusual myofilament Ca2+ sensitivity is a common observation with several 
cardiac diseases, including inherited (Hypertrophic, dilated, and restrictive) 
cardiomyopathies, as well as systolic and diastolic heart failure 192,195-197. Rodent 
studies have shown that correcting the sensitivity of the myofilament to Ca2+ with 
engineered troponins can correct disease-related changes in myofilament Ca2+ 
sensitivity and improve cardiac function 193,194. Thus, engineered troponins may 
serve as a new therapeutic strategy for treating cardiac diseases. This study 
aimed to test the hypothesis that engineered troponins can be used to either 
increase or decrease myofilament Ca2+ sensitivity in human myocardium. 
 
Consistent with rodent studies 100,194, engineered troponin complexes shifted the 
force-pCa relationship as predicted in human cardiac samples without altering 
maximal force production (Fig 5.3). The molecular basis for the increase or 
decrease in Ca2+ sensitivity as a result of the engineered TnCs and TnIs are not 
fully elucidated. However, several studies have shown that the TnC L48Q 
mutation increases the sensitivity of the myofilament to Ca2+ by causing an 
increase in the binding of both Ca2+ and TnI to TnC 198-200. Interestingly, the TnC 
L48Q mutation reduced the Hill coefficient in comparison to wild-type in the 
multicellular preparations. It is unclear why the TnC L48Q mutation decreased 
cooperativity in our human cardiac samples. However, consistent with our 
findings, Kreutziger et al. 201 reported that myocardium from rats with the TnC 
L48Q mutation demonstrated a similar reduction in the Hill coefficient when 
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compared to wild-type. In their manuscript, Kreutziger and coworkers 201 
suggested that the reduction in the Hill coefficient in cardiac samples with the 
L48Q mutation is likely the result of a decrease in the cooperative coupling 
between increased Ca2+ binding to TnC and strong cross bridge binding to actin. 
It is possible that this general hypothesis can also explain the reduction in 
cooperativity we see in our human cardiac samples with the TnC L48Q mutation. 
Further studies are needed to test the molecular basis for the decrease in 
cooperativity in rodent and human hearts with the TnC L48Q mutation. 
 
 
Recently, Shettigar et al. 2017 194 showed that engineered TnC could modulate 
cardiac function in healthy and diseased rodent hearts in-vivo. The results of their 
study demonstrated that mice transfected with TnC L48Q before and after a 
myocardial infarction had increased cardiac function (contractility, ejection 
fraction, fractional shortening). More importantly, they did not see any changes in 
calcium transients or saw any signs of arrhythmias, all of which have been 
associated with inotropic agents. Thus, the findings of their study provided 
evidence that precisely formulated troponins can tune the response of the 
myofilament to Ca2+, and may serve as a novel therapy to combat heart disease. 
The findings of this study would suggest that similar results may be possible in 
human hearts, as engineered TnCs and TnIs were able to modulate myofilament 
responsiveness to Ca2+ in human cardiac samples. 
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Chapter 6 
Summary 
This chapter will provide an overview of the main findings reported in chapters 2- 
 
5. Each chapter will be divided into sections that first report the main results of 
each study, followed by the clinical implications. The chapter ends with a 
discussion tying together the main results of each chapter. 
 
 
6.1. The Ca2+ sensitivity of right ventricular myocardium increases more 
than the Ca2+ sensitivity of left ventricular myocardium in human heart 
failure (chapter 2) 
 
 
Summary 
 
The results of this study presented three important results. First, human heart 
failure increases the Ca2+ sensitivity of right ventricular myocardium more than 
the calcium sensitivity of left ventricular myocardium. Second, this contractile 
effect is likely to involve inter-ventricular differences in posttranslational 
modifications to sarcomeric proteins including TnI. Third, heart failure depresses 
maximum force and maximum power by similar amounts in tissue from both 
ventricles. 
 
 
Clinical implication 
 
Clinically, RV dysfunction has been under-appreciated, as it was believed that 
RV failure was primarily the result of impaired LV function 37. However, several 
studies have shown that left-sided and right-sided heart failure can develop 
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independently of each other 39,40,42. The results of this study would suggest that 
therapeutics designed to alter myosin kinetics to enhance cardiac function does 
not have to be chamber specific, as mechanical parameters implicit of myosin 
kinetics (maximum force, maximum power, the rate of tension recovery) did not 
differ between the ventricles. However, these data imply that caution should be 
taken when considering treating patients with agents that enhance myofilament 
Ca2+  sensitivity, as the impact on the RV and LV may differ. 
 
6.2. Omecamtiv mecarbil increases Ca2+ sensitivity and decreases the rate 
of force development in failing human hearts (chapter 3) 
 
 
Summary 
 
The results of the omecamtiv mecarbil study demonstrated that the drug 
increased calcium sensitivity and decreased the rate of tension development in a 
dose-dependent manner in human cardiac samples. Additionally, the drug did not 
have any significant impact on the maximally activated force. From motility 
assays, (not performed as a part of this dissertation, but was a part of the paper 
findings were reported in) it was proposed that OM increased calcium sensitivity 
and slowed force development by increasing the amounts of myosin heads in the 
strong force generating state (increased duty ratio). Additionally, the results of 
the motility assay suggest that the reduction in the force development could be 
the result of OM trapping a population of myosin heads in a detached or weakly 
bound state with actin. 
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Clinical implication 
 
Omecamtiv mecarbil is currently in phase II clinical trial. Phase I reports showed 
that the drug increased left ventricular ejection time, ejection fraction, fractional 
shortening, and stroke volume in a dose-dependent manner in healthy subjects 
126,202. In patients with stable heart failure (phase II) omecamtiv mecarbil 
increased ejection time and stroke volume 143 but did not demonstrate any of 
these effects in patients with acute heart failure (phase IIb) 203. A clinical 
parameter not reported in clinical trials papers that our study suggest OM may 
adversely impact is relaxation. The implications from this study are that the 
higher the OM concentration, the longer the muscle will take to relax. 
 
 
6.3. Para-Nitroblebbistatin reduces maximum force and calcium sensitivity 
in human myocardium (chapter 4) 
 
 
Summary 
 
In permeabilized multicellular preparations from human myocardium, para- 
Nitroblebbistatin reduced maximum force, maximum power, and calcium 
sensitivity without altering the rate of force development or shortening velocity. 
Results from in vitro motility assays (performed by collaborators) suggest that the 
molecule can reduce force, power and calcium sensitivity by reducing the myosin 
duty ratio. 
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Clinical implication 
 
Para-Nitroblebbistatin is a molecule used for research purposes, but the 
mechanism by which the compound acts is of a large clinical significance, as a 
drug with similar properties may be able to treat patients suffering from 
hypertrophic cardiomyopathy (HCM). The molecule binds to myosin, slowing the 
rate of phosphate release during the actin-myosin cycle, thus reducing the 
myosin duty ratio. The findings of this study suggest that patients who suffer from 
HCM may benefit from a drug with a similar mechanism of action, as these 
patients often suffer from a hypercontractile heart. Recently, a small molecule 
named MYK-461 was identified as a novel cardiac myosin inhibitor 183. Like 
blebbistatin, the drug was shown to reduce myosin duty ratio. Thus it may serve 
as a treatment for patients suffering from HCM. The drug is currently in clinical 
trial 204. 
 
6.4. Engineered troponins modulate the Ca2+ sensitivity of the 
failing human myocardium (chapter 5) 
 
 
Summary 
 
This study aimed to determine if engineered TnCs and TnIs could alter calcium 
sensitivity in human myocardium. The results of the study showed that 
engineered TnCs and TnIs could be used to either increase or decrease 
myofilament calcium sensitivity in cardiac samples from humans without altering 
myosin kinetics. 
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Clinical implication 
 
The recent advances in gene vector technology, design, and delivery modalities 
have made cardiovascular gene therapy a promising option for patients suffering 
from cardiac disease. Recently, a clinical trial was conducted using gene-based 
therapy to correct dysfunctional sarcoplasmic/endoplasmic reticulum Ca2+ 
ATPase pump activity in patients with heart failure 205. The findings demonstrate 
that gene therapy can be used to safely deliver genetic material to the heart 206, 
as well as provide benefits to the patients 207. In the present study, engineered 
TnCs and TnIs were able to modulate calcium sensitivity in human cardiac 
samples. The clinical implication of these data is that engineered proteins along 
with gene therapy have the potential to treat patients suffering from various forms 
of heart disease. 
 
 
6.5. Discussion 
 
A consistent finding in each of the studies presented in this dissertation is an 
alternation in myofilament calcium sensitivity. In chapter 2, we saw that calcium 
sensitivity was higher in the LV of non-failing hearts, and that heart failure made 
the RV was more sensitive to calcium. In chapters 3 and 4, the data showed that 
the use of omecamtiv mecarbil increased myofilament calcium sensitivity 
whereas para-Nitroblebbistatin decreased the sensitivity of the myofilaments to 
calcium. Finally, in chapter 5, the findings demonstrated that engineered 
troponins could be used to either increase or decrease myofilament calcium 
sensitivity. 
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As a reminder, myofilament calcium sensitivity is a concept researcher use to 
simplify the complex dynamic contraction/relaxation processes of cardiac muscle 
into a two variable system that describes the relationship between the 
concentration of free Ca2+ ions available to bind TnC and the amount of force the 
muscle generates 187. In a beating heart, changes to myofilament calcium 
sensitivity are essential to its function, as an increase may lead to increased 
contractility, as well as impaired relaxation. Conversely, a decrease may result in 
faster relaxation rates and reduced contractility. Thus, the ability of the heart to 
maintain and/or alter the sensitivity of the myofilaments to Ca2+ is essential for 
normal function. The discussion sections of chapters 2-5 have outlined the 
observed changes in myofilament calcium sensitivity and described how each 
could potentially alter cardiac function. Therefore, the global cardiac implications 
of those findings will not be discussed any further. 
 
 
A concept that has not been discussed in this dissertation is how changes in 
calcium sensitivity can modulate cardiac structure. This concept has grown over 
the years has studies have shown a correlation between changes in myofilament 
calcium sensitivity and cardiac diseases that alter cardiac structure 62,208. 
Hypertrophic cardiomyopathy (HCM) and dilated cardiomyopathy (DCM) are 
cardiac diseases commonly associated with changes in myofilament calcium 
sensitivity 208. Phenotypically, HCM results in a hypertrophic heart that is 
hypercontractile and has impaired relaxation; contrarily, DCM first causes an 
enlargement of the left ventricular wall followed by dilation (weakening), resulting 
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in systolic dysfunction (i.e., reduced ejection fraction) 209,210. The cause of HCM 
and DCM are commonly mutations within sarcomeric proteins that either 
increase (HCM) or decrease (DCM) myofilament calcium sensitivity 211-214. As a 
result, a paradigm as emerged that associates an increase in myofilament 
calcium sensitivity with HCM and a decrease to DCM. The results of the troponin 
study (chapter 5) demonstrate how mutations in sarcomeric proteins can either 
increase or decrease myofilament Ca2+ sensitivity. However, the mechanism by 
which changes in myofilament calcium sensitivity lead to HCM or DCM remains 
unclear. The question has to how do changes in myofilament Ca2+ sensitivity 
translate into cardiac disease have been asked by the field for decades, and to 
date, there are no definitive answers. 
 
 
Recently, a study published from the laboratory of Jeffery Molkentin asked this 
very question. In their study, Davis et al. 215 mutated TnC in vivo in mice to either 
increase (L48Q) or decrease (I61Q) myofilament calcium sensitivity. The results 
showed that L48Q enhanced myofilament calcium sensitivity, increased fractional 
shortening, slowed relaxation, and lead to a hypercontractile heart. However, the 
hearts of the mice with the L48Q mutations showed no change in cardiac growth 
or chamber dimensions up to 1 year of age 215. Thus, these animals did not 
display the hallmark HCM phenotype. Similar results were shown by Shettigar et 
al. 194. Unlike previous studies, Davis and coworkers 215  believed that the effects 
of the L48Q mutation on cardiac growth were being masked by the high 
contractile state and heart rate of mouse hearts, as well as enhanced diastolic 
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functions. Thus, they used the β-blocker metoprolol to try and unmask these 
effects. When metoprolol was administered to the animals, the data showed that 
the L48Q mutation causes an HCM like phenotype, as left ventricular wall and 
septal wall thickness increased 215. The use of isoproterenol reversed these 
effects the effects of metoprolol. Thus, the group concluded that the L48Q 
mutation could lead to HCM like phenotype; however, in a mouse, these effects 
are masked by the β-adrenergic drive which enhances relaxation and Ca2+ decay 
times. They also showed that the I61Q (reduced myofilament Ca2+ sensitivity) 
mutation causes DCM in mice, which can be corrected by adding a known HCM 
causing myosin mutation to increase Ca2+  sensitivity 215. 
 
One of the key findings in the study by Davis et al. 215 was the correction of the 
I61Q-dependent dilated heart growth with the R403Q myosin mutant allele. The 
results of that experiment suggested that myocytes can change their growth 
profile by sensing aberrations in the magnitude and time of tension generated at 
a given cytosolic Ca2+ concentration 215. The group goes on to show through a 
series of experiments that the decrease in myofilament tension as a result of 
altered myofilament Ca2+ binding in I61Q mice is linked to fluxes in the 
sarcoplasmic Ca2+, which alters cytoplasmic Ca2+ concentration. They then 
proposed that the alteration in cytoplasmic Ca2+ initiates a Ca2+dependent 
signaling pathway that leads to the remodeling of the heart. 
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The proposed signaling pathway that leads to cardiac growth as a result of 
changes in myofilament Ca2+ sensitivities by Davis et al. 215 is not quite clear. 
Additionally, it is not universal for all mutations that alter Ca2+ sensitivity, as they 
did not see morphological changes in the L48Q mice that were not given a β- 
blocker. Furthermore, there are mechanotransduction pathways in cardiac cells 
that may also lead to cardiac remodeling 216. Further studies are needed to fully 
understand how changes in myofilament Ca2+ sensitivity leads to cardiac 
disease. However, the manuscript by Davis et al. 215 has provided substantial 
evidence that altered myofilament Ca2+ sensitivity can induce cardiac growth by 
altering the tension generated by the myofilaments. 
 
 
With the understanding that an increase or decrease in myofilament Ca2+ 
sensitivity can lead to cardiac remodeling, there are implications not discussed in 
the previous chapters about the Ca2+ sensitivity data that can be inferred. For 
example, in the study comparing the mechanical properties of the LV and RV 
(chapter 2), it may be possible that the LV is thicker than the RV and can 
generate more pressure as a result of the myofilaments of the LV being more 
sensitive to Ca2+. A more concerning implication of the Ca2+  sensitivity data 
comes from the drugs (chapters 3 & 4) and engineered troponin (chapter 5) 
studies. In the drugs and troponin studies, it was shown that small molecules and 
engineered proteins could be used to either increase or decrease myofilament 
Ca2+  sensitivity. Considering the tension generation idea described by Davis et 
al. 215 is may be possible that continuous administration of omecamtiv mecarbil or 
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MYK-461 could lead to cardiomyopathy, as these drugs can increase or 
decrease myofilament tension generation respectively. Considering this theory, it 
would be interesting to perform a study to see how the continuous administration 
of these drugs over a long period modulate the morphology of the heart. The use 
of engineered proteins to either increase or decrease myofilament Ca2+ 
sensitivity also pose the same possibility of causing cardiomyopathy, which was 
demonstrated in the study by Davis et al. 215. Thus caution should be taken when 
considering this form of therapy. 
 
 
The findings in this dissertation have provided information addressing a general 
cardiac biology question (chapter 2), as well as information on how potential 
therapies (chapters 3, 4, and 5) may alter the mechanical properties of human 
hearts. These data will provide a significant contribution to the field, as the results 
are either being revised for publication (chapter 2), being prepped for submission 
(chapter 5) or have already been published (chapters 3 & 4). As it pertains to 
future studies, an interesting study would be to repeat the potential therapeutics 
studies (chapters 3, 4, and 5) with different myofilament lengths. This would be a 
unique study, as it would address two question, 1) how does length-dependent 
activation (activation of the myofilament at different lengths) influence the mode 
of action for each of these therapies, and 2) how does each treatment impact 
length-dependent activation. 
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